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The Preface: 










“I hope that my achievements in life shall be these—
that I will have fought for what was right and fair, 
that I will have risked for that which mattered, and 
that I will have given help to those who were in need, 
that I will have left the earth a better place for what 
I’ve done and who I’ve been.” 
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Four years ago, I first stepped foot on the Regis University campus, and 
since that time I have experienced many different thoughts, ideas, and theories 
that have ultimately lead to this thesis. My time at Regis has been a time of 
learning both inside and outside of the classroom. My academic path through 
Regis has primarily revealed itself through the combination of three avenues of 
learning: an education in neuroscience, the liberal arts core curriculum, and the 
honors program curriculum. In addition to these avenues of learning, I have also 
learned a great deal outside of the classroom through conversations with other 
members of the Regis community, as well as my involvement on campus. The 
goal for this thesis is to draw upon all aspects of my education, both academic 
and non-academic, as well as integrate the values and beliefs that are at the core 
of who I am as a human being.  
The most influential portion of my life for the last four years has been the 
time I have spent at Regis University. Most of my time at Regis has been spent in 
the classroom or studying, as it should be; and most of my time in the classroom 
has been spent in the neuroscience department, as it should be. All kidding aside, 
I have gained a tremendous appreciation for the human brain, the nervous 
system, and how these structures influence who we are as people during my 
time at Regis. As a result of these interests, neuroscience has become my major, 
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the focus of my education for the past few years, and now a primary focus of my 
thesis project.  
Although neuroscience has played a major role in my academic career, the 
summation of all my areas of study has determined my overall, Regis education. 
Regis University has a rather vast core curriculum, as it is a liberal arts college. 
At times this has been a burden, as I would prefer to spend my time in the 
neuroscience laboratory, but in retrospect, I am glad for the numerous disciplines 
I have encountered. Regis emphasizes the importance of a well rounded 
individual, and the core curriculum is one way of accomplishing this emphasis. 
A person is only able to be knowledgeable in the world by knowing a little of 
everything, and it is often true that one discipline will inform another, further 
enhancing an individual’s intellectual prowess. I have learned that 
interdisciplinary learning is the most challenging, but also the most rewarding 
and applicable to the real world. Because of this, I have aimed to create an 
interdisciplinary thesis, in which I not only approach a neuroscience topic but 
some other aspect of the topic as well. 
The final avenue of learning that has guided me through my education at 
Regis has been the honors program. The honors program curriculum is 
interdisciplinary in nature, but is also more than that. The honors program 
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emphasizes the importance of asking one’s self very difficult questions. Such 
questions include: how can tradition inform innovation, what is justice, and how 
does one find meaning? These questions do not have universal answers, but they 
must be thought about because of the ways that they inform an individual’s life. 
Whether conscious or not, every individual must have a meaning for their life as 
well as a clear conception of what is just. Without these beliefs, no individual 
could carry out simple everyday tasks such as waking up in the morning or 
going to work. One must have a purpose for his or her life, and then carry his or 
her passion into all the work that he or she takes part in. Likewise, a person must 
know how to live justly through his or her work, friendships, and every day 
interactions. In summary, the honors program has helped me solidify my own 
beliefs and encouraged me to continue asking questions that may or may not 
have answers. In regards to this thesis, the honors program has confirmed my 
belief that it must be interdisciplinary, but it also directed me to look for a thesis 
topic that I find personally important.  
Bringing all three of these avenues into conversation, I concluded that this 
thesis should attempt to answer a challenging question, be interdisciplinary in 
nature, be grounded in neuroscience, and most of all, be of value to me. In order 
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to narrow in on the topic of this thesis, posttraumatic stress disorder, I looked to 
my experiences outside the classroom.  
A major influence in my life is my family, and a good portion of my 
family is military. Additionally, I have thought heavily about joining the military 
as I pursue a career as well. Thus, the military seemed to be an appropriate area 
to explore. With some research and a lot of thought, I began to investigate 
posttraumatic stress disorder. Through my neuroscience background, I had been 
exposed to the tragedies of the disorder and the impairments that it may cause, 
but it was not until I began investigating the disorder apart from neuroscience 
and psychology that I fully realized the issues surrounding the disorder. For 
instance, veterans and legislators have been in a heated agreement over the 
question: should war veterans with PTSD be given a purple heart? This further 
leads to an even greater question, how is physical injury different from mental 
injury? The answer to this question is not easily answered, but it is generally 
agreed upon that mental injury is indeed different than physical injury. Physical 
injury, no matter how severe, will not change the person’s personality, 
perceptions, or memories unless there is a mental side effect to the physical 
damage. On the contrary, mental injury has a great impact on all these aspects of 
the person’s identity. From this stance, I decided to explore the possibilities of 
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treating PTSD. In almost all circumstances, a person will correct a physical injury 
if possible. With PTSD, however, this is not an option. Although there is ample 
research looking into treatments for PTSD, there currently is not a treatment to 
prevent or relinquish PTSD symptoms. Due to my personal connection to the 
military, I decided to contribute to PTSD research and study the effects of 
propranolol (an experimental drug) on PTSD symptoms. In short, I see the 
ultimate goal of PTSD research, and my thesis, as helping those suffering from 
PTSD cope with the disorder and possibly restore their pre-trauma quality of 
living.  
The foundation of my thesis is to experimentally test the effects of 
propranolol as it relates to PTSD symptoms. However, this does not fulfill all the 
requirements I had set for myself in creating this thesis project. From the time I 
began proposing my experiment, I also began to question the possible impacts of 
a drug that would treat PTSD. How could a drug simply wipe away one’s 
memory or completely dissociate the emotional impact of such a memory? And 
if this could really happen, should it? Much of my life has been informed by the 
memories I have. I believe that I am not simply one person, but a summation of 
every person I have been at each point in my life. In other words, I am who I am 
because of my experiences; my value of memory is very high. Thus a personal 
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conflict arises. I have a desire to help suffering individuals, but through certain 
forms of helping, one may remove key elements of that person’s identity and 
alter his or her future self. At this cost, is treating the disorder still helping? In this 
conflict, I discovered the second portion of this thesis. Through asking tough 
questions, such as what is the value of suffering, how can one give informed 
consent for such a treatment, and how does religion impact such a treatment 
decision, I decided to explore whether treating PTSD would be ethically possible, 
and if so, would the treatment of PTSD bring justice to the victim. 
This thesis is my attempt to give attention to a topic that is controversial, 
but also deeply rooted in the lives of many. At the conclusion of this thesis, I 
would like to have a universal answer to the questions I have raised, but I cannot 
guarantee this will be the result. What I can guarantee is that I will have a greater 
understanding of the topic and will have insights that I did not have at the start 
of this project. I also hope that you gain a better understanding of the topic at 
hand as a result of my work here. It is true that a thesis is more than a document 
to be read. A thesis springs from a need or question in the world, and has the 
potential to create a change. In conclusion, I propose that we all ask the tough 
questions and begin to seriously consider the impacts of the decisions we make 
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whether they be monumental, such as treating a patient with PTSD, or every day, 
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An introduction to posttraumatic stress disorder (PTSD): 































PROPRANOLOL AND PTSD 
 
- 10 - 
 
The popular expression “What does not kill you makes you stronger” 
points to some people’s ability to respond to trauma resiliently. However, for 
those same traumas, a more appropriate statement may be “What does not kill 
you can make you ill” or “What does not kill you might as well have.” There are 
many individuals who are not resilient to trauma, and when faced with a 
traumatic experience, their lives are forever altered. Even those who are highly 
resilient may develop a serious psychological disorder depending on the severity 
of the trauma. Approximately one tenth of those who survive life-threatening 
events will develop a mental health disorder, such as posttraumatic stress 
disorder (PTSD) (Jovanovic & Ressler, 2010). Although PTSD was once thought 
to be relatively uncommon, recent estimates suggest that between 10 and 39 
percent of all people will suffer from PTSD during their lives (Cantor, 2005, p.7). 
PTSD is a serious issue, and is one that needs to be addressed. 
Although the diagnostic criteria for PTSD have only been in place since 
1980, the symptoms associated with PTSD have been around for much longer. 
Symptoms associated with PTSD, such as high levels of anxiety, heightened 
startle response, nightmares, and emotional reliving of experiences have existed 
since the pre-Christian period (Parry-Jones & Parry-Jones, 1994). Although PTSD 
is no longer a new term, the disorder has been around for a much longer period 
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under other pseudonyms. Since the mid-nineteenth century, PTSD-type 
symptoms have been given numerous titles such as: spinal concussion, railway 
spins, and irritable heart from the 1860s; soldier’s heart and cardiac weakness 
from the 1870s; traumatic shock, traumatic neurosis, hysterical hemianaesthesia, 
spinal irritation, railway brain, and nervous shock from the 1880s; anxiety 
neurosis and psychical trauma from the 1890s; traumatic neurosis, shell fever, 
irritable heart of soldiers, mental shock, war shock, shell shock, neuro-circulatory 
asthenia, disordered action of the heart, and war psychoneurosis from the 1910s; 
cardiac/war neurosis form the 1930s; and battle fatigue/combat exhaustion and 
effort syndrome from the 1940s (Parry-Jones and Parry-Jones, 1994). Each of 
these terms referred to what is now known as posttraumatic stress disorder. It 
was not until 1980, when posttraumatic stress disorder was added to the third 
edition of the Diagnostic and Statistical Manual for Mental Disorders that PTSD 
became a generally accepted term for such abnormal responses to severe trauma 
(Cantor, 2005). 
The Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) 
provides the following diagnostic criteria for PTSD (2000). For an individual to 
be diagnosed with PTSD, the person must have been exposed to a traumatic 
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event in which the person experienced, witnessed, or was confronted with an 
event or events that involved actual or threatened death or serious injury, or a 
threat to the physical integrity of self or others. Additionally, the person’s 
response to the experience must involve intense fear, helplessness, or horror. The 
victim must also persistently re-experience the traumatic event through visual 
images, thoughts, dreams, or mental recreation of the event. The person must 
avoid stimuli associated with the trauma and have persistent symptoms of 
increased arousal. Finally, the duration of the disturbance must be more than one 
month (American Psychiatric Association [DSM-IV-TR], 2000). These are the 
symptoms that an individual must present to be classified as experiencing PTSD. 
PTSD-influencing traumas are more common than one may think. Such 
traumatic experiences do not only happen during war or high conflict situations, 
but also during everyday life.  For example, several of the earlier terms for PTSD 
involved the railway due to the traumatic scenes of train crashes during that time 
period. One notable victim of such a crash was Charles Dickens. A train crash left 
his carriage swaying precariously from a bridge, and upon emerging from his 
carriage he was greeted with the sight of dead and injured all around him 
(Cantor, 2005). Although PTSD was not recognized as a diagnosis at the time, 
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Charles Dickens’ experiences in the train crash nearly 150 years ago closely 
resemble what many sufferers of acute stress and PTSD go through today. 
Although people who have been tortured and/or victimized for long 
periods of time suffer the highest rates of PTSD and that prisoners of war and 
concentration camp survivors have a 50% rate of chronic PTSD, the prevalence of 
PTSD resulting from other everyday-type traumatic experiences is significant as 
well (Cantor, 2005). Civilians too face surprisingly high rates of exposure to 
traumatic stressors during their normal, everyday routine, including rape, 
terrorist attacks, death of a loved one, childhood abuse, natural disasters, and a 
wide variety of other severe psychological traumas (Heim & Nemeroff, 2009). 
Survivors of natural disasters have rates of PTSD around 4% (Cantor, 2005). 12% 
of individuals involved in a motor vehicle accident, which has a lifetime 
prevalence of 23%, develop PTSD (Cantor, 2005). Assault is another trauma 
which may result in PTSD. Thirty percent of non-sexual assault case victims and 
50% of rape victims will develop PTSD within three months of the trauma 
(Cantor, 2005). Traumas associated with war and combat are leading causes of 
PTSD, but traumas of everyday life also lead to PTSD symptoms. These PTSD 
causing trauma are linked by their uncontrollability. 
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When all the possible PTSD-producing traumatic events are summed 
together, the prevalence of PTSD shows itself to be quite high. Posttraumatic 
stress disorder is a serious anxiety disorder with a lifetime prevalence of 
approximately 6.8% in the United States and a 12 month prevalence of 3.8% 
(Adamec, Muir, Grimes, & Pearcey, 2007). Given that 50-60% of all North 
Americans experience a traumatic stress in their lifetimes, and 15% of these 
traumatically stressed individuals will subsequently develop PTSD, PTSD has 
become a serious issue and the topic of much research (Adamec, Muir, Grimes, & 
Pearcey, 2007). Further enhancing the need for a better understanding of PTSD is 
the fact that approximately 30% of patients experiencing PTSD will still be 
suffering from the disorder at least ten years after the trauma (Langevin, De 
Salles, Kosoyan, & Krahl, 2010). This is highly troubling because research has 
shown that if PTSD symptoms have not been resolved within 6 years, the 
symptoms are highly likely to remain chronic (Cantor, 2005).  
Currently, the three most common treatment methods for PTSD are 
cognitive behavior therapy, eye movement desensitization and reprocessing 
(EMDR), and stress management (Ponniah & Hollon, 2009). Trauma-focused 
cognitive behavior therapy involves repeated exposure to the traumatic memory 
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through cognitive methods and then progressively changing the individual’s 
thought processes and behaviors towards the trauma. EMDR utilizes dual 
attention tasks to help the patient process the traumatic event. EMDR involves 
the patient focusing on negative trauma-related memories while engaging in a 
task involving some form of bilateral stimulation, such as eye movements, until 
distress has decreased and belief in more positive trauma-related thoughts has 
increased. Stress management does not focus on the trauma, but involves the 
patient’s learning skills to help manage anxiety. Such skills consist of slow, 
abdominal breathing, relaxation techniques, learning to use positive statements 
and self-talk strategies, distraction techniques, and assertiveness training.  
Although these three treatments prove helpful for some patients suffering 
from PTSD, 30% of patients who develop PTSD will still be suffering from 
treatment ten years following the trauma (Langevin, De Salles, Kosoyan, & 
Krahl, 2010, p. 1241). This prevalent rate reflects that the current treatments for 
PTSD do not meet all of the needs of those affected. Although there have been 
significant advances in the understanding of PTSD, treatment failures persist. As 
a result, researchers have subsequently begun studying the effects of possible 
pharmacological interventions. 
PROPRANOLOL AND PTSD 
- 16 - 
 
 While the goal of any study focusing on a disease or disorder is to find a 
cure, the mechanisms through which the disorder or disease arises must first be 
understood so that an effective treatment may be found. It is generally accepted 
that the symptoms of PTSD reflect stress-induced changes in neurobiological 
systems and/or an inadequate adaptation of neurobiological systems to exposure 
of severe stressors. However, it is not clear which specific neurological systems, 
neurotransmitters, or brain structures are affected by the traumatic experience(s), 
and subsequently, elicit PTSD.  
Various aspects of the nervous system have been implicated in the 
pathophysiology of PTSD, including the hypothalamic-pituitary-adrenal (HPA 
axis), the hippocampus, the amygdala, the prefrontal cortex, as well as six 
neurotransmitters and neuropeptides. Each of these brain structures, systems, 
and neurotransimtters play a role in the regulation of fear, the response to stress, 
or memory consolidation, and have attracted much attention regarding the study 
of the etiology of PTSD and the any potential treatments for the disorder.  
The neurocircuitry that has been scrutinized most closely in PTSD patients 
has been the HPA axis, an organism’s major neuroendocrine stress response 
system (Heim & Nemeroff, 2009), which is responsible for coordinating the 
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body’s response to stress (Yehuda, 2000). Upon exposure to a stressor, neurons in 
the hypothalamic paraventricular nucleus (PVN) secrete corticotrophin-releasing 
factor (CRF). CRF is then transported to the anterior pituitary where it stimulates 
the production of adrenocoricotropin (ACTH). ACTH, in turn, stimulates the 
release of glucocorticoids from the adrenal cortex. Glucocorticoids exert effects 
on metabolism, immune function, and the brain to adjust physiological functions 
and behavior to the stressor (Heim & Nemeroff, 2009). In short, a stressor affects 
a cascade of hormones that eventually results in the release of cortisol from the 
adrenal cortex, which functions to manage the body’s biological stress response 
by stimulating the termination of neural defense reactions that have been 
activated by stress (Yehuda, 2000).  These mechanisms cause the HPA axis to be 
the major system in which trauma is managed.  
Studies of the HPA axis in patients with PTSD have revealed low cortisol 
levels in patients with PTSD regardless of the type of trauma, an individual’s age 
at traumatization, the duration of PTSD symptoms, or the age of the subjects at 
the time of biological assessment (Heim & Nemeroff, 2009; Yehuda, 2000). 
Cortisol serves a regulatory function in the CNS. Decreased cortisol levels result 
in PTSD because less cortisol equates to an individual’s lessened ability to 
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manage their biological response to trauma. This inability to manage one’s 
biological response to trauma results in the sustained activation of neural 
systems involved is stress reactivity and fear processing (Heim & Nemeroff, 
2009). All considered, it seems that cortisol levels are directly associated with the 
severity of PTSD symptoms.  
Several brain pathways modulate HPA axis activity. The hippocampus 
and prefrontal cortex inhibit the HPA axis, whereas the amygdala and 
monoaminergic input from the brainstem stimulate the activity of neurons 
associated with the HPA axis (Heim & Nemeroff, 2009), creating an interest in 
these pathways as well. The most reproducible finding in structural imaging 
studies of PTSD is reduced volume of the hippocampus. The hippocampus is 
implicated in the control of stress responses, declarative memory and contextual 
aspects of fear conditioning (Heim & Nemeroff, 2009). A preponderance of 
neuroimaging data from the past decade demonstrates that PTSD patients have 
greater amygdala activation relative to comparison subjects; brain imaging 
studies (PET and fMRI) have found that the amygdala modulates the fear 
response (Jovanovic & Ressler, 2010). Furthermore, recent functional magnetic 
resonance imaging (fMRI) studies have found that trauma-relevant words as 
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well as trauma-specific imagery increase amygdala activation (Jovanovic & 
Ressler, 2010). In much the same way, the prefrontal cortex is implicated in 
PTSD. Recent studies have demonstrated that neurons in the prefrontal cortex 
have inhibitory action on the amygdala (Jovanovic & Ressler, 2010). Exaggerated 
fear responses observed in PTSD and the impaired inhibition on conditioned 
inhibition tasks is thought to be due to a weakened inhibitory control of the 
amygdala by the prefrontal cortex in combination with a lack of control over 
stress responses due to alterations in hippocampal volume. Ultimately, several 
brain regions are currently implicated in PTSD.  
Yet, like most mental disorders, it is likely that the unfavorable stress 
response to a traumatic event in PTSD is influenced by an imbalance in 
neurotransmitters, whether due to overproduction, inactivation, or an alteration 
at the receptor sites. Several neurotransmitters and neuropeptides are involved 
in the body’s response to stress, and thus, are of interest in PTSD research. The 
implicated neurotransmitters are norepinephrine, serotonin, GABA, glutamate, 
neuropeptide Y, and opioids (Heim & Nemeroff, 2009). Norepinephrine is 
believed to play the greatest role in an individual’s response to trauma and the 
memory consolidation of such trauma. 
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Before discussing norepinephrine, the effects of serotonin, GABA, 
glutamate, neuropeptide Y, and opiods as related to PTSD symptoms should be 
discussed. Serotonin helps to regulate sleep, appetite, sexual behavior, 
aggression and impulsivity, motor function, and neuroendocrine control (Heim 
& Nemeroff, 2009). Serotonin neurons of the dorsal raphe projecting to the 
amygdala and hippocampus mediate stress-increasing effects via serotonin 
receptors (Heim & Nemeroff, 2009). Chronic exposure to stressors induces 
upregulation of these serotonin receptors (Heim & Nemeroff, 2009). Altered 
serotonin transmission may contribute to a subset of the symptoms of PTSD that 
includes hypervigilance, increased startle response, impulsivity, and intrusive 
memories. Additionally, treatment with GABA agonists decreases symptoms of 
anxiety in PTSD, and exposure to stressors increases glutamate release in the 
brain (Heim & Nemeroff, 2009). Neuropeptide Y inhibits CRF and 
norepinephrine circuits involved in stress and fear responses (Heim & Nemeroff, 
2009). Thus, a lack of neuropeptide Y promotes a maladaptive stress response 
and contributes to the development of PTSD (Heim & Nemeroff, 2009). 
Endogenous opioids such as endorphins or enkephalins inhibit the HPA axis, 
and alterations are involved in symptoms of numbing, stress-induced analgesia, 
and dissociation in PTSD (Heim & Nemeroff, 2009). Opiates have the ability to 
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dampen central noradrenergic hyperactivity, and consequently PTSD symptoms 
(Strawn & Geracioti, 2008). Clearly, neurotransmitters are not without an effect 
on the development and sustainment of PTSD. 
The major stress response neurotransmitter is norepinephrine. 
Norepinephrine is the major central catecholamine, and is derived from neurons 
of the locus coeruleus. These neurons project to many structures that are 
involved in the pathophysiology of PTSD. Structures affected by norepinephrine 
include the prefrontal cortex, amygdala, hippocampus, hypothalamus, 
periaqueductal gray matter and thalamus (Liberson et al., 1999; Phan et al., 2006; 
Pissiota et al., 2002). Norepinephrine largely affects the regulation of arousal and 
autonomic stress responses. Norepinephrine (NE) is produced by the adrenal 
medulla through sympathetic stimulation and the local effects of cortisol, and 
provides positive feedback to the pituitary gland maintaining the stress response 
and further stimulating the HPA axis (Vermetten & Bremner, 2002). 
Norepinephrine is also thought to play a role in the encoding of memories 
(Vermetten & Bremner, 2002). Norepinephrine exerts it effects by binding to 
alpha or beta adrenoreceptors. Beta receptors are linked to G-protein systems, 
and promote its effects by the increase of adenylyl cyclase. In contrast, alpha 
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receptors are associated with a myriad of biochemical effectors; alpha receptors 
effects are also transduced through a G-protein system (Strawn & Geracioti, 
2008). To reduce the effects of norepinephrine at each of these receptors, 
antagonists for each of the receptors may be introduced. Although antagonist for 
alpha as well as beta receptors have proved effective at reducing the effects of 
norepinephrine, beta blockers are more centrally acting (Strawn & Geracioti, 
2008). Norepinephrine has been a central candidate in studying the 
pathophysiology of PTSD (Heim & Nemeroff, 2009).   
Combat veterans, abused women, and children with PTSD have increased 
levels of norepinephrine in their urine (Heim & Nemeroff, 2009). A couple of 
studies have investigated the excretion of catecholamines following sexual abuse. 
De Billis et al. (1994) found increased levels of norepinephrine 24 hours after the 
abuse, and Lemieux and Coe (1995) documented increased levels of 
norepinephrine excretion later in life for the individuals who go on to develop 
PTSD related to childhood sexual abuse. Likewise, combat veterans with PTSD 
show increased levels of norepinephrine excretion 24 hours after trauma 
compared to patients with major depression, bipolar mania, paranoid 
schizophrenia, undifferentiated schizophrenia, and healthy control subjects 
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(Kosten et al., 1987; Yehuda et al., 1992). While many studies have assessed 
urinary concentrations of norepinephrine, not all of them have observed 
increased levels of norepinephrine in patients with PTSD (Glover and Loland, 
2002). This finding is likely due to norepinephrine’s inability to cross the blood-
brain barrier. Peripheral concentrations do not well reflect norepinephrine 
concentrations (Strawn & Geracioti, 2008). Patients with PTSD have tonically 
elevated norepinephrine concentrations in the central nervous system, and 
central nervous system norepinephrine is robustly secreted in response to acute 
psychological stress (Geracioti et al., 2001). Clinically, evidence shows that 
norepinephrine plays a role in an individual’s response to stress, and if PTSD 
develops, increased amounts of norepinephrine are produced.  
Based on its strong role in the body’s stress response systems, 
norepinephrine has been a central target in researchers’ attempts to develop a 
preventative treatment for PTSD. One of these norepinephrine-targeting drugs is 
a long-chain beta-blocker called propranolol. Propranolol is a non-selective beta-
adrenergic antagonist that binds to peripheral and central β-adrenergic receptors 
and readily crosses the blood-brain barrier (Vaiva et al., 2003). Thus, propranolol 
may be used to block β-noradrenergic receptors in the amygdala after fear 
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memory training blocks consolidation of the fear memory. Although attempts to 
mitigate PTSD symptoms with post stressor block of β-noradrenergic receptors 
with propranolol have been successful (Pitman et al., 2002; Reist et al., 2001; 
Vaiva et al., 2003), some research has found propranolol ineffective in treating 
PTSD symptoms (Cohen et al., 2011). For example, Pitman et al. (2002) reported 
that propranolol given within 6 hours of a traumatic event for 10 days was 
superior to a placebo for reducing PTSD symptoms 1 month after trauma. 
Similarly, Vaiva and colleagues (2003) found that when compared to eight 
traumatized patients who did not receive propranolol, only one in 11 treated 
patients developed PTSD developed PTSD two months after the trauma, 
whereas PTSD developed in three of the eight untreated patients. Evidence has 
been reported that administration of propranolol shortly after exposure to 
psychological trauma reduces PTSD symptom severity and reactivity to 
reminders of the traumatic event (Heim & Nemeroff, 2009). The present study 
will test propranolol as an experimental treatment for PTSD as defined in a rat 
model. 
Although several studies have experimentally tested PTSD in human 
trauma victims and the results have shown to affect PTSD symptoms, the 
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research is not conclusive that propranolol is an effective treatment to prevent 
PTSD. This study will attempt to influence an animal model of PTSD, and 
subsequently test propranolol as a preventative treatment for PTSD-like 
symptoms in rats exposed to a life-threatening stressor.  
The criteria for influencing PTSD in an animal model should include the 
same criteria as deemed necessary for a diagnosis of PTSD by the DSM-IV-TR. 
There should be the application of direct physical stressors in conjunction with 
exogenous stimuli that closely mimic those seen in nature. Furthermore, the 
stressors should influence a fear for one’s life. When these criteria are followed, 
stressed rats tend to show PTSD-like behavior such as increased immobility, 
decreased grooming and rearing, decreased exploratory behavior and decreased 
food consumption (Kesner et al., 2009). Thus, fear conditioned behavior, which is 
similar to PTSD symptoms, should be able to be accomplished via the 
implementation of appropriate stressors. It should be noted that chronic PTSD 
cannot be elicited in animals due to the ethical constraints that are put on the 
mistreatments that may be put on animals for scientific purposes.  In most cases, 
conditioned fear is taken as the animal model of PTSD.  
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The present study will first strive to develop an animal model of PTSD in 
rodents, and then attempt to evaluate the effects of propranolol on PTSD-like 
symptoms. In the present study, rats will be exposed to inescapable shocks at a 
rate of one shock per thirty seconds for ten minutes on a variable interval 
schedule. This direct stressor will be paired with the scent of bobcat urine in 
order to create a trauma eliciting PTSD. Rodent behavior - levels of anxiety, 
burying behavior, and freezing behavior - will be observed pre- and post- trauma 
to indicate whether rat behavior has changed in response to the traumatic 
experience. Given that the rodent behavior does change, propranolol will then be 
used as a treatment for PTSD symptoms. All in all, this study will address three 
guiding questions for the research: 1) Can an accurate animal model for PTSD be 
developed? 2) Does propranolol, a β-noradrenergic antagonist, reduce PTSD 
symptoms? 3) Does propranolol reduce PTSD symptoms via the blockage of β-
noradrenergic receptors in the brain?  
My hypotheses are that (1) PTSD behavior will be altered in response to a 
traumatic experience, and subsequently that symptoms similar to PTSD behavior 
can be observed in an animal model, (2) propranolol will effectively reduce the 
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severity of PTSD symptoms, and (3) propranolol prevents the development of 
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THE EFFECTS OF PROPRANOLOL,  
A NON-SELECTIVE β-ADRENERGIC ANTAGONIST, 
ON RAT BEHAVIOR IN AN ANIMAL MODEL OF  
POSTTRAUMATIC STRESS DISORDER 
 





Abstract: To date, very little is known about the neurocircuitry of posttraumatic 
stress disorder, and currently 5.2 million people are suffering from PTSD in the 
United States alone. In hopes to treat PTSD symptoms, researchers have targeted 
corticosteroids, beta-adrenergic antagonists, and opiate analgesics to reduce 
hormonally enhanced memories and fear conditioning. This study focuses on 
testing propranolol, a beta-adrenergic antagonist, as a treatment for PTSD-like 
symptoms (anxiety and freezing behavior) in a rat model. Rats were exposed to 
inescapable, moderate shocks paired with a predator scent to elicit PTSD-like 
symptoms. Propranolol was shown to effectively reduce anxiety at 28 days post 
stress, but did not affect freezing behavior. Through this study, data concerning 
the time course for PTSD in an animal model was obtained. 
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The popular expression 
“What does not kill you makes you 
stronger” points to the fact that some 
people respond to trauma resiliently. 
While this response may be true for 
highly resilient people, a more 
appropriate general statement may 
be “What does not kill you can make 
you ill” or “What does not kill you 
might as well have.” Many 
individuals are not resilient to 
trauma, and when faced with a 
traumatic experience, their lives are 
forever altered. Even those who are 
highly resilient may develop a 
serious psychological disorder 
contingent on the severity of the 
trauma. Approximately one tenth of 
those who survive life-threatening 
events will develop a mental health 
disorder, such as posttraumatic 
stress disorder (PTSD) (Jovanovic & 
Ressler, 2010). This equates to 5.2 
million people suffering from PTSD 
in the United States (Adamec, Muir, 
Grimes, & Pearcey, 2007). 
In general terms, PTSD is a 
debilitating psychological condition 
triggered by a major traumatic event. 
In addition to war, the stereotypical 
traumatic experience leading to 
PTSD, civilians in modern societies 
also face surprisingly high rates of 
exposure to traumatic stressors, 
including rape, terrorist attacks, the 
death of loved ones, childhood 
abuse, natural disasters, and several 
other severe psychological traumas 
(Heim & Nemeroff, 2009). Whatever 
the trauma, all traumatic events are 
marked by uneasy memories or 
thoughts of the ordeal, emotional 
instability, increased arousal, and/or 
personality changes (Heim & 
Nemeroff, 2009). However, 
additional symptoms may develop.  
The Diagnostic and Statistical 
Manual for Mental Disorders (DSM-
IV-TR) provides diagnostic criteria 
for PTSD (American Psychiatric 
Association [DSM-IV-TR], 2000). For 
an individual to be diagnosed with 
PTSD, the person must have been 
exposed to a traumatic event in 
which the person experienced, 
witnessed, or was confronted with 
an event or events that involved 
actual or threatened death, serious 
injury, or a threat to the physical 
integrity of self or others (American 
Psychiatric Association [DSM-IV-
TR], 2000). The person’s response to 
the experience must involve intense 
fear, helplessness, or horror. The 
victim must persistently re-
experience the traumatic event 
through visual images, thoughts, 
dreams, or mental recreation of the 
event. The individual must avoid 
stimuli associated with the trauma 
and have persistent symptoms of 
increased arousal. Finally, the 
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duration of the disturbance must be 
more than one month (American 
Psychiatric Association [DSM-IV-
TR], 2000).  
Posttraumatic stress disorder 
is a serious anxiety disorder with a 
lifetime prevalence of approximately 
6.8% in the United States and a 12 
month prevalence of 3.8%. 50-60% of 
all North Americans experience a 
traumatic stress in their lifetimes, 
and 15% of these traumatically 
stressed individuals will 
subsequently develop PTSD 
(Adamec, Muir, Grimes, & Pearcey, 
2007). Furthermore, approximately 
30% of patients will still be suffering 
from PTSD at least ten years after the 
trauma (Langevin, De Salles, 
Kosoyan, & Krahl, 2010). This 
finding is highly troubling because 
research has shown that if PTSD 
symptoms have not been resolved 
within 6 years, the symptoms are 
highly likely to remain chronic 
(Cantor, 2005).  
The symptoms of PTSD reflect 
stress-induced changes in 
neurobiological systems and/or an 
inadequate adaptation of 
neurobiological systems to exposure 
to severe stressors. However, it is not 
clear which specific neurological 
systems, neurotransmitters, or 
abnormal brain structures cause 
PTSD. Neurobiologicial systems that 
have been implicated in the 
pathophysiology of PTSD include 
the hypothalamic-pituitary-adrenal 
(HPA) axis, and various 
neurotransmitters and 
neuropeptides that comprise a 
network of brain regions that 
regulate fear and stress responses. 
These include the prefrontal cortex, 
hippocampus, amygdala, and 
brainstem nuclei (Heim & Nemeroff, 
2009). The neurocircuitry that has 
been scrutinized in PTSD patients 
has been the HPA axis. The HPA 
axis is an organism’s major 
neuroendocrine stress response 
system which affects metabolism, 
immune function, and the brain, 
adjusting physiological functions 
and behavior to stress (Heim & 
Nemeroff, 2009). The HPA axis' 
sensitivity is increased after a 
traumatic event by a strong negative 
feedback of cortisol which is due to 
the highly increased sensitivity of 
cortisol receptors (Heim & Nemeroff, 
2009). Another mediator of HPA axis 
activity is norepinephrine. 
Norepinephrine (NE) is produced by 
the adrenal medulla through 
sympathetic stimulation and the 
local effects of cortisol, and provides 
positive feedback to the pituitary 
gland maintaining the stress 
response and further stimulating the 
HPA axis (Vermetten & Bremner, 
2002). Norepinephrine is also 
thought to play a role in the 
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encoding of memories (Vermetten & 
Bremner, 2002). 
The present study will focus 
primarily on the development and 
course of PTSD as it relates to the 
secretion of NE. Because of its 
multiple roles in regulating arousal 
and autonomic stress responses 
through its interaction with the HPA 
axis, as well promoting the encoding 
of emotional memories, NE has been 
a central candidate in studying the 
pathophysiology of PTSD (Heim & 
Nemeroff, 2009). NE is one of the 
principal mediators of the central 
nervous system (CNS) and 
autonomic stress responses. The 
majority of CNS NE is derived from 
neurons of the locus ceruleus (LC) 
that project to various brain regions 
involved in the stress response, 
including the prefrontal cortex, 
amygdala, hippocampus, 
hypothalamus, periaqueductal grey, 
and thalamus (Heim & Nemeroff, 
2009).  Accordingly, increased 
urinary excretion of NE and 
epinephrine has been documented in 
combat veterans, abused women, 
and children with PTSD (Strawn & 
Geracioti, 2008).   
Many approaches to the 
treatment of PTSD have been taken, 
in animal models as well as in 
humans. While the diagnostic 
criteria for PTSD have only existed 
since 1980, hundreds of clinical trials 
have sought to identify methods of 
ameliorating its distressing 
symptoms (Cukor, Spitalnick, 
Difede, Rizzo, & Rothbaum, 2009). 
Current treatments for PTSD include 
psychological interventions 
including social and family based 
therapy, behavioral treatments, 
imagery-based treatments, therapies 
focusing on distress tolerance, 
“power” therapies, and 
technological-based treatments 
(Cukor et al., 2009). Although there 
have been significant advances in the 
treatment of PTSD, treatment 
failures persist. 
Another form of treatment is 
pharmacological treatment, and is 
the focus of recent research 
pertaining to PTSD treatment and 
prevention. Over the past decade, 
many compounds have been tested 
as treatments for PTSD. 
Corticosteroids, beta-adrenergic 
antagonists, and opiate analgesics 
have been shown experimentally to 
reduce hormonally enhanced 
memories and fear conditioning 
(Cohen, Kozlovsky, Matar, Kaplan, 
& Zohar, 2010). Propranolol, a beta-
adrenergic antagonist, has received 
great attention, and is hypothesized 
to decrease the consolidation of 
stressful memories due to its 
inhibitory affects on NE receptors, 
and indirectly the HPA axis. 
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The focus of the present study 
is on the efficacy of propranolol as a 
preventative treatment for the 
development of PTSD following a 
traumatic experience. Propranolol is 
a non-selective beta-adrenergic 
antagonist that binds to peripheral 
and central β-adrenergic receptors 
and readily crosses the blood-brain 
barrier (Vaiva et al., 2003). Thus, 
propranolol may be used to block β-
noradrenergic receptors and the 
consolidation of the fear memory. 
Attempts to mitigate PTSD 
symptoms with post stressor block 
of β-noradrenergic receptors by 
treatment with propranolol have 
mixed results, but there is evidence 
that propranolol reduces PTSD 
symptom severity (Pitman et al., 
2002; Reist et al., 2001; Vaiva et al., 
2003). Propranolol given within 6 
hours of a traumatic event for 10 
days was superior to a placebo for 
reducing PTSD symptoms 1 month 
after trauma (Pitman et al., 2002). 
Vaiva and colleagues studied motor-
vehicle accident survivors and the 
effects of propranolol on the 
development of PTSD. Vaiva et al. 
found that in comparison to eight 
traumatized patients who did not 
receive propranolol, treatment with 
propranolol was superior. Only one 
in 11 treated patients developed 
PTSD two months after the trauma, 
whereas PTSD developed in three of 
the eight untreated patients (Vaiva et 
al., 2003). Although some research 
has found propranolol ineffective in 
treating PTSD symptoms (Cohen et 
al., 2011), the majority of evidence 
has found that the administration of 
propranolol shortly after (or before) 
exposure to psychological trauma 
reduces PTSD symptom severity and 
reactivity to reminders of the 
traumatic event (Heim & Nemeroff, 
2009).  
This study attempts to 
determine the effectiveness of 
propranolol as a preventative 
treatment for PTSD symptoms. In 
order to accomplish this, an animal 
model of PTSD was influenced, and 
the treatment tested in the animal 
population. To date, little research 
has been completed in an animal 
model.  
The criteria for inducing 
PTSD in an animal model should 
include the same criteria as a 
diagnosis of PTSD by the DSM-IV-
TR. There should be the application 
of direct physical stressors in 
conjunction with exogenous stimuli 
that closely mimic those seen in 
nature. Furthermore, the stressors 
should create a fear for one’s life. 
When these criteria are followed, 
stressed rats tend to show PTSD-like 
behavior such as increased 
immobility, decreased grooming and 
rearing, decreased exploratory 
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behavior and decreased food 
consumption (Kesner et al., 2009).  
The present study strives to 
develop an animal model of PTSD in 
rats, and then attempt to evaluate 
the effects of propranolol on PTSD 
symptoms. Rats are exposed to 
inescapable shocks paired with the 
scent of bobcat urine in order to 
create a trauma eliciting PTSD. Rat 
behavior (levels of anxiety, burying 
behavior, and freezing behavior) is 
observed pre- and post-stress to 
indicate whether rat behavior has 
changed in response to the traumatic 
experience. Given that rodent 
behavior changes, propranolol is 
used as a treatment for PTSD 
symptoms. All in all, this study 
addresses two guiding questions for 
the research: 1) Can an accurate 
animal model for PTSD be 
developed? and 2) Does propranolol, 
a β-noradrenergic antagonist, reduce 
PTSD symptoms in a rat model?  
My hypotheses are that (1) rat 
behavior will be altered in response 
to a traumatic experience, and 
subsequently that symptoms similar 
to PTSD behavior can be observed in 
an animal model and (2) propranolol 








All procedures were carried out 
under strict compliance with ethical 
principles and guidelines of the NIH 
Guide for the Care and Use of 
Laboratory Animals. All treatment 
and testing procedures were 
approved by the Intuitional Animal 
Care and Use Committee of Regis 





Dawley rats were used throughout 
the study. The animals were housed 
singly or in pairs in a cage with a 
width of 10 inches, a length of 18.5 
inches, and a height of 8 inches. The 
conditions in the animal facility were 
controlled at 72 oF. The animals were 
held in an environment with a 
twelve hour light – twelve hour dark 
cycle (06:00—18:00 light). All 
animals had food and water 
available ad libitum. The cage 
bedding was changed every 2-3 
days.   
 
2.2. Experimental design 
 
The study consisted of two 
main experiments, each assessing the 
effectiveness of propranolol as a 
treatment for post-traumatic stress 
disorder in an animal model but 
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differing in the behaviors assessed. 
The independent variables were the 
stress and treatment conditions. The 
stress conditions were either stress 
exposure or no stress exposure. The 
treatment conditions were either no 
treatment, a saline injection, or a 
propranolol injection. The dependent 
variables were the rats’ ball burying 
behavior, elevated plus maze 
performance, and freezing behavior.  
 
2.2.1 Experiment 1 
 
Experiment 1 consisted of two 
parts. Part 1 intended to develop an 
animal model of PTSD. Rats were 
randomly assigned to one of two 
conditions, an inescapable stressor 
condition or a control condition. In 
the inescapable stressor condition, 
each rat was exposed to moderate 
shocks (shocks of 0.5 second 
duration and 1.5 mA intensity) 
occurring at 30 second variable 
intervals for 10 minutes, combined 
with a predator stress, bobcat urine. 
All stress exposures occurred in a 
standard operant chamber. During 
the stress exposure period, the rat 
was exposed to a novel object, a soft-
flight golf ball.  The control animals 
were exposed to fresh, unsoiled 
cedar chips and received no shock, 
but were exposed to the novel object. 
Neither the experimental rats nor the 
control rats received any treatment 
after the stressors during Part 1 of 
the experiment.  
Part 2 of Experiment 1, 
followed the same protocol. 
However, after the stress exposure 
period, the animals were 
immediately injected with a 10 
mg/kg dose of propranolol 
intraperitoneally.  
To evaluate whether the rats 
developed PTSD-like behavior, two 
assessment strategies were used in 
Part 1 of Experiment 1, and all 
assessment was completed at 7 days 
as well as 28 days post stress 
exposure. First, the novel object, the 
soft-flight golf ball, was placed back 
with the rat, in its normal living 
conditions, for fifteen minutes, to 
assess the rat’s burying behavior. 
Rats bury a novel object when it has 
been paired with a traumatic 
experience (Harvey et al., 2006). The 
second assessment tool was an 
elevated plus maze, which was used 
to assess anxiety. The dimensions of 
the maze were 64.5 inches by 64.5 
inches. Each arm was 30 inches in 
length.  
 
2.2.2. Lever pressing training 
protocol 
 
Prior to the start of 
Experiment 2, the animals were 
trained to press a lever in the 
operant chamber for a sugar pellet 
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reward. The training process shaped 
the rats’ behavior. Each rat was 
placed in an operant chamber and 
shaped to stay the one side of the 
chamber with the levers, then to rear 
up on that side of the chamber, and 
eventually to press the right or left 
lever. When a rat performed a 
desired behavior, it was rewarded 
with a sugar pellet reward.  
Lever pressing behavior was 
reinforced until the animal was able 
to receive at least 50 sugar pellets 
within 20 minutes; first at a ratio of 
one lever press to one sugar pellet, 
and then at a ratio of 5 lever presses 
to one sugar pellet. To achieve this 
level of conditioning, four successful 
reinforcement trials were utilized. 
Each animal was placed in an 
operant chamber and allowed to 
receive 50 sugar pellets for itself via 
pressing either the left or right lever. 
Once this mark had been reached in 
two successive trials, the animal was 
removed from the chamber. After 
two trials of training on the one lever 
press to one sugar pellet fixed ratio, 
the animal was trained to press the 
lever five times to receive one sugar 
pellet. Each training session on this 
five lever presses to one sugar pellet 
fixed ratio lasted until the animal 
received at least 50 sugar pellets. 
Two 5:1 fixed ratio training sessions 
took place.  
 
2.2.3 Experiment 2 
 
Experiment 2 consisted of 
three parts. All three parts of this 
study were based on the rats’ ability 
to press a lever to receive a 45 mg 
sugar pellet. Before Part 1 of the 
study began, the rats’ rate of lever 
pressing for a sugar pellet reward 
(on a 5:1 fixed ratio) was assessed 
and recorded as a control measure 
for lever pressing behavior. 
Part 1 of Experiment 2 further 
focused on developing an animal 
model for PTSD, but used freezing 
behavior, rather than burying 
behavior or anxiety, as the 
predicative factor of PTSD. After 
being trained to press the lever in an 
operant chamber, the rats were 
placed into the operant chamber and 
exposed to inescapable, moderate 
shocks (shocks of 0.5 second 
duration and 1.5 mA intensity) 
occurring at 30 second variable 
intervals for 10 minutes, as well as a 
predator stress, bobcat urine. A 
bright light was paired with each 
shock. During this session the rats 
were still able to press the lever to 
receive a sugar pellet (at a 1-to-1 
fixed ratio). At 7, 14, and 21 days, the 
rate of lever pressing for each rat 
from Part 1 of Experiment 2 was 
assessed in the presence of the bright 
light, to assess the degree of freezing 
each rat expressed.  
PROPRANOLOL AND PTSD 
 
- 36 - 
 
Part 2 of Experiment 2 
followed the same protocol as Part 1 
of Experiment 2. However, a 10 
mg/kg intraperitoneal injection of 
propranolol was given immediately 
following the stress exposure period. 
The assessment strategy for Part 2 of 
Experiment 2 was identical to that of 




Propranolol (15 mg/kg) was 
dissolved in saline and administered 
via intraperitoneal injection. 
Controls received an equivalent 
volume of 0.9% saline solution in the 
same manner, controlling the 
potentially stressful effects of an 
intraperitoneal injection. The drug or 
vehicle solutions were freshly 
prepared and injected at the same 
time of day in a volume of 1 ml/kg 
body weight. 
 
2.4. Behavioral measurements 
 
Over the course of the two 
studies, an elevated plus maze and 
lever press rate comparisons were 
used to assess anxiety and freezing 
behavior, which are indicative of 
PTSD-like symptoms. All behavioral 
measurements were recorded by the 
experimenter at the time of 
assessment. 
 
2.4.1. The elevated plus-maze 
 
In Experiment 1, the rats were 
assessed on the elevated plus maze 
(EPM). The EPM creates a conflict 
situation between the exploratory 
drive of rodents and their aversion 
to open spaces (Pellow et al., 1985). 
The maze consists of two open arms 
and two closed arms. The maze 
forms a “+” with the open arms and 
closed arms lying along their 
respective axes. The maze was raised 
24 inches above the floor. The rat 
was placed in the center of the 
apparatus facing an open arm and 
allowed to explore the maze for 5 
minutes under constant observation. 
An arm entry was considered when 
all four paws crossed from one arm 
and into the other. The amount of 
time spent in the open arm versus 
the amount of time spent in the 
closed arm was recorded. The more 
time the animal spent in the closed 
arm, the higher degree of anxiety the 
animal was believed to have. An 
image of an EPM is displayed in 
Figure 1. 
To assess the degree of 
anxiety exhibited by the rat, the rats’ 
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The higher the anxiety ratio, the 
greater the amount of anxiety the rat 
expresses. 
 
2.4.2. Ball burying behavior 
 
 The frequency of ball burying 
is predicative of PTSD in an animal 
model. Although burying is a rare 
behavior in wild rats, it is thought to 
represent the symptoms of PTSD 
when it follows a stress exposure 
period (Mikics et al., 2008). The 
animals were exposed to the soft-
flight tennis ball for a 15 minute 
period at 7days post stress as well as 
28 days post stress. The amount of 
time the animal spent burying the 
ball, exploring the ball (sniffing, 
biting, or grabbing the ball), and the 
amount of time spent ignoring the 
ball was observed and recorded by a 
single examiner.  
 
2.4.3. Rate of lever pressing 
 
 The two previous methods of 
assessment (used in Experiment 1) 
did not measure the degree of 
freezing which is a hallmark trait of 
PTSD in an animal model. In 
Experiment 2, the degree of freezing 
was assessed by comparing the pre-
stress rate of lever pressing with the 
rate of lever pressing 7, 14, and 21 
days following the traumatic 

























used to assess the rate of lever 
pressing post trauma in order to 
account for the press rate when the 
light was on as well as when the 




The suppression ratio is inversely 
proportional to the degree of 
suppression. As the suppression 
ratio decreases, the amount of 
suppression increases. 
 
Figure 1. – Detailed image of an elevated plus maze. 
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The greater the difference in 
these measures pre and post stress, 
the higher degree of freezing the 
animal has had. The control animals 
were assessed at the time of stress, 
although they themselves were not 
stressed, 7, 14, and 21 days after the 
stress. This provides an indication of 




3. Results  
 
3.1.  Experiment 1 - Effect of stress, 
propranolol, and time on anxiety-
like behavior and ball burying 
behavior.  
 
Experiment 1 assessed the 
degree of anxiety exhibited by the 
rats as well as the degree of avoidant 
behavior exhibited by the rat.  
The anxiety ratios were 
analyzed for effects of stress (stress 
or no stress), treatment (immediate 
administration of a propranolol 
injection or a saline injection), and 
time (7 days post trauma or 28 days 
post trauma). A univariate ANOVA 
revealed that there was no 
significant effect of stress on anxiety, 
F(1,27) < 1.  
However, the treatment 
condition did appear to show an 
effect. The rats who received the 
saline injection had a mean anxiety 
ratio of .819 ± .241 while the rats who 
received the propranolol injection 
had a mean anxiety ratio of .692 ± 
.344. Some rats received propranolol 
and were observed 7 days post 
stress; the mean anxiety ratio of this 
group was .910 ± .103. Others were 
observed 28 days post stress; the 
mean anxiety ratio of this group was 
.540 ± .375. There was a main effect 
of treatment on anxiety, F(1,27) = 



























Figure 2. – This figure illustrates the mean 
anxiety ratios of the control group, saline group, 
and propranolol group 28 days after the stress 
trial. The difference between the control rats and 
the rats who received the stress with no 
treatment was insignificant 28 days after the 
stress trial. However, the administration of a 
propranolol injection following the stress trial 
significantly reduced the anxiety ratio expressed 












injected rat at 
28 days post 
stress 
Propranolol 
injected rat at 
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Time also had a significant 
effect on the rats’ anxiety. The mean 
anxiety ratio of rats assessed 7 days 
post stress was .910 ± .103. The mean 
anxiety ratio of rats assessed 28 days 
post stress was .700 ± .306. There was 
also a main effect of time on anxiety, 





























Experiment 1 also assessed 
ball burying behavior by the rats as a 
measure of avoidant behavior. Only 
four of 31 rats (28 of which were 
stressed) exhibited any degree of ball 
burying behavior. There were no 
effects of stress (F(1,27) < 1), 
treatment (F(1,27) = 2.493, p = .126), 
or time (F(1,27) < 1) on ball burying 
behavior 
 
3.2.  Experiment 2 - Effect of 
propranolol and time delay until 
assessment on post-stress freezing 
behavior 
 
Experiment 2 aimed to 
evaluate the rat model of PTSD used 
in the present study by assessing 
freezing behavior as a result of the 
stress induced. In order to initially 
test freezing behavior due to the 
induced stress, a baseline rate of 
lever pressing was observed pre-
stress and then each rat’s post stress 
lever press rate was observed 7, 14, 
or 21 days after the stress was 
administered. A t-test was 
conducted on baseline lever press 
rate and post stress lever press rate. 
The post-test rate of lever pressing 
was significantly lower than the 
baseline rate of bar pressing 
behavior (t(32) = 5.977, p < .001). 
Upon establishing that the 
animal model of PTSD significantly 
affected the rats’ bar press rates, a 
 
 
Figure 3. – This figure focuses on the effectiveness 
of propranolol over time. The effect of time on 
anxiety ratio is significant in that if causes the 
anxiety ratio to increase, even when propranolol 
was administered as a treatment, at seven days 
post stress but decrease beyond the level of pre-
morbid functioning at 28 days post stress (when 












injected rat at 
7 days post 
stress
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univariate ANOVA was conducted 
to determine the effects of the 
treatment condition and time 
condition on press rate behavior. The 
baseline press rate was covaried in 
order to eliminate any effects that the 
rat’s baseline press rates may have 
on the analyses.  
Propranolol did not have a 
significant effect on lever press rate 
as indicated by the rats’ suppression 
ratios. The rats that were given a 
saline injection had a mean 
suppression ratio of .545 ± .110. The 
rats given a propranolol injection 
had a mean suppression ratio of .590 
± .121. The effect of propranolol on 
lever press rate was insignificant, 
F(2,23) = 1.99, p = .158, ηp2 = .148.  
The effect of time did 
significantly affect the rats’ lever 
press rate as indicated by their 
suppression ratios. The rats’ mean 
suppression ratio when observed 7 
days after stress was .529 ± .101.  The 
rats’ mean suppression ratio when 
observed 14 days after stress was 
.642 ± .107. The rats’ mean 
suppression ratio when observed 21 
days after stress was .495 ± .088. The 
amount of time elapsed between 
stress and observation was 
significant, F(2,23) = , p = .002, ηp2 = 
.409 (Figure 4). 
A pairwise comparison of the 
time data indicates that the mean 
suppression ratio of rats observed at 
week one is significantly lower than 
the mean suppression ratio of rats 
observed at week two, p = .004, and 
that the mean suppression ratio of 
rats observed at week three is 
significantly lower than the mean 
suppression ratio of rats observed at 
week two, p = .001. The suppression 
ratios of rats observed at weeks one 






























Figure 4. – This figure focuses on the effect of time 
on suppression ratio as a measure of freezing 
behavior, F(1,23) = 7.962, p = .002. As time 
increased since the stressor, the degree of 
suppression measured had increased at the 14 day 
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4.1.  Discussion of results found in 
Experiment 1  
 
 The main findings from 
experiment 1 were threefold: 1) there 
is no effect of the stressful experience 
used in this experiment on the rats’ 
anxiety ratios, 2) propranolol did 
effectively reduce the rats’ amount of 
anxiety 28 days after the stress 
experience, and 3) the time course 
data suggests that the rats’ anxiety 
ratio increased at 7 days post-stress 
but had normalized back to the 
control measure by 28 days post 
stress.  
 The finding that the stressful 
experience does not affect the rats’ 
levels of anxiety 28 days post trauma 
(as indicated by the EPM data) 
suggests that either the stress 
experience used to elicit PTSD-like 
behavior did not significantly affect 
the rats’ level of anxiety or 
potentially that laboratory rats are in 
a perpetual state of anxiety  and 
stress. An argument can be made 
that the present stress protocol did 
not alter anxiety levels or elicit 
PTSD-like symptoms because of the 
procedure of the present study. 
Support for this claim comes from 
the lack of burying behavior by the 
rats in response to the stress and 
treatment. However, Langevin et al. 
(2010) claims that burying behavior 
is a rare behavior in wild rats. 
Burying behavior would have 
suggested that the rat wanted to flee 
the object associated with the stress 
experience. If the stress procedure 
was not sound, the rats may have 
paired the memory of the stress 
experience with the operant chamber 
rather than the novel object, 
explaining why burying behavior 
did not occur. Another plausible 
explanation is that the rats simply 
did not know how to bury.  
The rats may not have 
exhibited changes in anxiety ratios 
because they were already anxious. 
The continual handling, 
transportation, and movement of the 
laboratory rats, in addition to their 
unnatural housing environment, 
may lead the animals to be in a 
constant state of anxiety. Data 
presented in Experiment 1 supports 
both of these theories. 
 In order to confirm one of 
these theories, further 
experimentation must be completed. 
First, it would be useful to use the 
current procedure and collect the 
same data again, but to also collect 
data at 7 days post-stress for the 
anxiety ratio of rats that were given a 
saline injection. It would also be 
beneficial to calculate the anxiety 
ratios and observe the burying 
behavior of rats (in the same control 
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and experimental groups) when 
stressed with a different stress 
protocol. A time dependent 
sensitization stress paradigm using 
restraint and forced swimming have 
also been effective in eliciting PTSD 
in an animal model (Harvey et al., 
2006). 
 Another significant finding is 
that propranolol effectively reduces 
rats’ level of anxiety 28 days post-
stress. This finding supports that 
propraonol effectively reduces 
anxiety (Pitman et al., 2002; Vaiva et 
al., 2003). The claim that the stress 
experience does alter the rats’ level 
of anxiety because it causes the rat to 
lose all recollection of emotions 
associated with the experience seems 
to be supported. 
 Propranolol does not show 
this same effect 7 days post-stress. At 
7 days post-stress, the mean anxiety 
ratio is increased from the control 
measure (the anxiety ratio of non-
stressed rats) to 0.910. Although the 
anxiety ratio has increased, 
propranolol was not proven effective 
at 7 days post stress for decreasing 
the rats’ anxiety ratio due to 
insufficient information. The anxiety 
ratio of saline injected rats 7 days 
post stress was not observed. Thus, 
propranolol may have an effect on 
rats’ anxiety ratios one week after 
stress, but if so, the effect is not great 
because the anxiety ratio still 
increased significantly from the 
control. Propranolol’s inability to 
reduce anxiety 7 day post trauma 
supports Cohen et al.’s (2011) claims 
that propranolol is ineffective in 
preventing PTSD.  
The data from Experiment 1 
also suggests that there is a time 
course associated with the 
effectiveness of propranolol or the 
presentation of PTSD-like 
symptoms. The data concerning time 
course shows that propranolol has 
greater effectiveness at 28 days, than 
at 7 days, post stress. Therefore, the 
data indirectly suggests that the rats’ 
anxiety level increases 7 days post 
stress, but then normalizes again by 
28 days post stress. The rats’ mean 
anxiety ratio increased at 7 days post 
stress despite the propranolol 
treatment, and then normalized at 28 
days post stress. These findings 
support a time course to be 
associated with PTSD symptoms, 
and that PTSD symptoms do not 
necessarily develop immediately 
following the trauma.  
 
4.2.  Discussion of results found in 
Experiment 1  
 
Experiment 2 yielded two 
findings worth further discussion: 1) 
propranolol did not significantly 
affect freezing behavior and 2) time 
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after stress influences the degree of 
freezing behavior in rats. 
 When propranolol treated 
rats’ freezing behavior (as indicated 
by the suppression ratio of lever 
pressing with the light on) was 
compared to the saline treated rats’ 
freezing behavior, there was not a 
significant effect. This may be 
explained in two ways. One 
explanation is that the propranolol 
administration did not effectively 
treat the symptoms elicited by the 
stress experience. For instance, one 
dose of propranolol immediately 
following the stress may not have a 
great enough effect on the rat. In 
human trials, a series of doses must 
be administered to see an effect on 
PTSD symptoms (Vaiva et al., 2003). 
Likewise, the one dose of 15mg/kg 
may not have significantly affected 
the rats’ behaviors or symptoms. The 
other issue may have arisen in the 
process of pairing the stressful 
experience with the novel object. It 
may be that the rat did not pair the 
stressful event with the novel object, 
but the operant chamber itself.  
 The data collected from 
Experiment 2, like Experiment 1’s 
data, suggest a time course for 
PTSD-like symptoms. The mean 
suppression ratio of rats observed at 
14 days post stress were greater than 
the suppression ratios of the rats 
observed at 7 days post stress, but 
the mean suppression ratio of rats 
observed 21 days after the stress 
were lower than the suppression 
ratios measured at 7 days post stress.  
Thus, the degree of suppression 
began to increase again between 14 
and 21 days post stress. Using 
freezing behavior as the determining 
factor of PTSD in an animal model, 
an animal model of PTSD may be 
developing by 21 days post stress, 
but does not begin to develop before. 
This data supports the data from 
Experiment 1, indicating that PTSD 
symptoms do not develop 
immediately after the stress.  
 
 
5. General Discussion 
 
Based on the results of the 
two experiments conducted in this 
study, neither of the two hypotheses 
presented at the beginning of the 
study were supported. The stress 
experience did not affect the rats’ 
ball burying behavior or anxiety 
level 28 days post trauma, and 
although propranolol did reduce 
anxiety, it did not significantly affect 
ball burying or freezing behaviors, 
which were also used as measures 
for PTSD symptoms. 
Despite rejection of the 
hypotheses, the present study does 
prove useful for future PTSD 
research. The pre and post stress 
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lever press rates and suppression 
ratios suggest that an animal version 
of PTSD was elicited in the rats. 
Likewise, if future research indicates 
that the lack of anxiety level 
increases at 7 days post stress, then it 
may be concluded that the stressful 
experience did in fact resemble a 
trauma that could elicit PTSD-like 
symptoms. The present protocol for 
eliciting PTSD-like symptoms may 
be slightly altered to truly determine 
if the present stress protocol does 
produce PTSD-like symptoms in rats 
and if propranolol effectively 
prevents such symptoms. 
Additionally, this data indicates that 
propranolol is effective for treating 
anxiety. The data also provides 
support for a delayed development 
of PTSD symptoms.  
The findings from this study 
suggest that PTSD symptoms do not 
develop immediately following the 
trauma, but take time to develop. In 
this rat model, PTSD symptoms do 
not begin to exhibit themselves until 
the third week after the stress 
experience. Evidently, posttraumatic 
stress disorder does exhibit itself in 
different patterns. Different 
individuals may respond to a single 
trauma very differently. Individuals 
may also differ in their presentation 
of the PTSD symptoms. Symptoms 
may appear immediately after the 
trauma or months or years later 
(Cantor, 2005). This study indicates 
that the time course for a rat to 
exhibit PTSD-like symptoms is 
approximately 3 weeks. Hopefully 
this study provides insight to future 
studies regarding the testing of 
PTSD and potential treatments of the 
disorder in the animal model.  
In conclusion, despite finding 
no significance of the effects of 
propranolol, this study was 
successful in unexpected respects 
and contributes to the neuroscience 
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The Afterword: 












“Everybody says we're all so different 
But everybody knows we're all the same 
We're all trying to find a pill to numb the pain 
Something's got to change” 
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The effects of propranolol, a non-selective β-adrenergic antagonist, on rat behavior 
in an animal model of posttraumatic stress disorder is the foundation for this thesis 
and provides new research to the field of neuroscience and PTSD literature. 
Through this study, the effects of propranolol on a rat version of PTSD, which 
was influenced through a stress protocol adapted from previous fear 
conditioning and PTSD studies, were tested. Propranolol did not effectively 
decrease all PTSD symptoms in this study, as I had expected, but I did find that a 
single 15 mg/kg dose of propranolol administered immediately after stress 
significantly reduced the rats’ freezing behavior 28 days after administration. I 
also found that the PTSD-like symptoms that the rats experienced had a distinct 
time course. Furthermore, this research has helped me generate more ideas for 
potential studies concerning the development of pharmacological treatments for 
PTSD. Ultimately, this study led me to insights regarding PTSD, propranolol, 
and PTSD research. 
Although the research completed, and presented in this thesis led to 
positive, yet unexpected, results, I realize that many ethical questions arise from 
this research as well. The present study did not support the hypotheses stated at 
the onset of the experiments or lead to any truly extraordinary findings in 
regards to a treatment for posttraumatic stress disorder (PTSD). It did however, 
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subject animals to psychological stress. Although researchers design experiments 
to yield results consistent with their hypotheses, this does not always occur. My 
study is not the only study that has ever failed to support its hypotheses, and it 
definitely will not be the last. The stresses of experimentation, however, are 
present across all research and are consistently impressed upon the research 
subjects or participants.  Thus, the question arises, should scientific research 
which causes any element of harm be tolerated? This complex question tends to 
polarize people. The views concerning scientific research, and each of its 
subtypes, range from fully condemning research to entirely supporting it as the 
most beneficial tool for furthering knowledge about the world. The use of 
animals as research subjects is a clear example of this polarization, and is another 
ethical concern brought about by my study. Why should one complete research 
on animals rather than humans? Is an animal’s life less valuable than the life of a 
person?  
In addition to the questions directly surrounding my research, questions 
surround the search for a treatment for PTSD. The overarching question is 
whether or not individuals suffering from PTSD should be provided a 
pharmacological treatment to prevent or reduce their symptoms. The initial 
response to this question may seem simple, but when the side effects of the 
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treatment(s) are taken into consideration, the answer becomes more convoluted. 
To treat PTSD, the memory of the trauma or the relationship one has with that 
memory must be treated. Most pharmacological treatments aim either to 
eliminate the memory completely or to blunt the emotions associated with the 
memory. Ethical questions arise concerning the value of one’s memory, the value 
of one’s emotions. After exploring these questions, one must also question how a 
pharmacological treatment may be implemented and the greater effects of a 
PTSD treatment on society. 
Questions like these often go overlooked in the scientific community, but 
regardless, it is important to investigate such ethical questions. Although it 
would be an amazing scientific feat to discover a treatment, one cannot ignore 
the ethical questions surrounding PTSD treatment research simply because of the 
scientific interest. It is also important to think about each ethical question 
individually, and not simply agree with the common answers to the ethical 
questions.  
Before I begin exploring the overarching question of whether or not a 
treatment of PTSD should be made available, I must address the ethical concerns 
of scientific research. In the following section I will outline the current stance of 
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the scientific community on scientific research that uses humans as research 
participants and that uses animals as research subjects. 
 
I. Current views of scientific research using humans as research 
participants and animals as research subjects 
 
The general view of the scientific community is that scientific research is 
justifiable with the participant consent to the investigation as long as no harm is 
deliberately imparted upon the participant. Immanuel Kant states that “a human 
being, and in general every rational being, does exist as an end in himself, not 
merely as a means to be used by this or that will as it pleases” (Sandel, 2007). I 
completely agree with this Kantian philosophy, and so does the scientific 
community. Although scientific research may not always produce the results that 
the researcher(s) believed it would, the benefits of scientific research will 
continue to outweigh the costs as long as the participants’ individual rights are 
respected and the ethical guidelines outlined above are upheld. If any form of 
research were proposed in which people were forced to participate in a study or 
the study infringed upon the participant’s rights, the research would not be 
allowed to occur. Each person should be treated equally, and guaranteed his or 
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her rights. In order to guarantee that each person is treated as an end in himself, 
ethical principles have been developed to guide scientific research.  
Three primary principles must be upheld in scientific research that uses 
humans as research participants. The first principle is respect for persons. This 
principle emphasizes the inherent dignity and worth of each person. The 
principle requires science to respect individuals and their autonomy; it means 
not treating people simply as a means to an end, but encouraging their right to 
self-determination and the right to make choices, to hold views, and to take 
actions based on personal values and beliefs. Based on this principle, one should 
always “act in such a way that you treat humanity…always at the same time as 
an end, never merely as a means” (Sandel, 2007).  The respect for persons principle 
emphasizes the responsibility individuals have for their own lives. The second 
principle has to do with maximizing benefits while minimizing harms. To maximize 
benefits one would help others and act in their best interests while creating the 
greatest wealth of new knowledge. Meanwhile, minimizing harms obligates 
others to minimize the amount of harm intentionally inflicted on the participant. 
The third principle relates to giving each person his or her due. This dictates that 
each person should qualify for equal treatment because each person is equally 
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human. All resources, risks, and costs should be equally available (NWABR, 
1999).  
In addition to these three principles, more pointed guidelines must also be 
followed. The American Psychological Association has outlined ten general 
principles governing the conduct of research with human participants. Among 
these principles are: gaining institutional approval for the research at hand (if 
necessary), gaining informed consent to research from the research subject, 
gaining informed consent for recording voices and images during research, 
ensuring protection of subordinate research participants (students, patients, 
clients, etc.) from adverse consequences of declining or withdrawing from 
participation, dispensing information only with informed consent and for a 
legitimate reason, offering reasonable inducements for research participation, 
minimizing deception in research, providing a debriefing session for the research 
participant(s), and caring for all animals involved in research in a humane 
manner (Elmes, Kantowitz, & Roediger III, 2006). Although these ethical 
guidelines are expansive, they are necessary to allow for the pursuit of 
knowledge through scientific research in an ethical manner. These principles are 
intended to protect the welfare of research participants, and they can be 
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summarized by noting that the experimenter has an obligation to minimize harm 
to the participant while treating him or her with respect and seeking to maximize 
the benefits that may be gained from the research.  
As long as the aforementioned ethical guidelines are upheld, scientific 
research and the resulting knowledge is not only ethical, but it is necessary. 
Science is the only avenue of learning for certain disorders. For instance, the 
etiology and treatment of psychological disorders cannot be understood without 
studying the individuals with the disorder or inducing such a disorder in an 
animal subject or human participant in order to test potential treatments. Even 
though some research has already been conducted on PTSD, very little is known 
about the disorder. While it is known that the hypothalamic-pituitary-adrenal 
(HPA axis), the hippocampus, the amygdala, the prefrontal cortex, as well as six 
neurotransmitters and neuropeptides are implicated in PTSD, it is not clear 
which abnormalities within the CNS actually lead to the development of PTSD 
symptoms. Thus, there is a tremendous need for more research on the 
neurological abnormalities that underlie PTSD. Perhaps if a person can 
understand the neurochemistry of PTSD he or she can find a treatment for the 
disorder. Without the ability to complete scientific research, treatments for 
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psychological disorders like PTSD would never be developed. As long as 
person’s rights are respected, scientific research that uses humans as participants 
is encouraged.  
The scientific community does not hold quite as stringent views on animal 
research. Although a better understanding of the neurobiology of PTSD may be 
obtained through the dissection of human brains that have experienced PTSD, 
and eliciting PTSD in humans rather than animals would lead to understand 
PTSD as it affects the human brain, these research techniques violate the ethical 
guidelines of human research. However, the scientific community is comfortable 
with using these same research techniques in animal models.  
Animals may be used for certain types of research that humans cannot 
because of the need for better scientific understanding of diseases and disorders 
as well as the logic that animals do not have the same moral rights as humans. 
Every effort should be made to do what is best for the individual and society as a 
whole. The pursuit of a treatment for PTSD, and any other psychological 
disorder, would allow for the individual to return to his or her premorbid level 
of functioning and a degree of suffering would be removed from the world. 
Animal research may be a way to obtain this objective. Cohen (1986) explains 
that animals are incapable of moral agency and therefore lack moral rights. 
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Rights only arise among beings that can actually make moral claims against one 
another. Animals do not have the capability of moral judgment, and therefore, 
do not have any rights (Cohen, 1986). Based on the knowledge to be gained from 
animal research coupled with the belief that animals do not have moral agency, 
the scientific community believes that animals should be appropriately used to 
advance biomedical research (Mappes & Degrazia, 2006). The scientific 
community allows animal research in the pursuit of furthering scientific 
knowledge.  
Although researchers are able to use animals as research subjects, they are 
not free to treat animals in any way that they see fit. Animals certainly suffer, 
and should not be made to suffer needlessly. It is accepted that animals do not 
have a moral status comparable to that of humans. This is evident through our 
willingness to set a mouse trap or prepare a boiling pot of water for a lobster 
dinner. However, it is also generally agreed upon that animals have certain 
liberties. The biomedical and animal protection communities both agree on the 
following: the use of animals in biomedical research raises ethical questions, 
sentient animals deserve moral protection, animals are capable of having a wide 
variety of aversive mental states (including pain, distress, and suffering), and 
animals’ overall well-being deserves protection (Hettinger, 1989). On the other 
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hand, these communities also agree that promoting human health is extremely 
important and that there are some morally significant differences between 
humans and other animals (Hettinger, 1989). From these beliefs, it is accepted 
that animal research is justified only when the ethical guidelines for animal 
research are followed.  
The Council for International Organizations of Medical Sciences (CIOMS) 
assumes that the moral status of animals does not preclude the need for animal 
use in research. At the same time, CIOMS asserts that researchers have certain 
responsibilities to minimize the animal’s pain, distress, and discomfort and must 
use alternatives to animal research whenever possible (Mappes & Degrazia, 
2006). In accordance with the CIOMS’s view, Bear et al. (2007) gives three main 
responsibilities that neuroscientists must uphold when conducting neuroscience 
research with animal subjects.  
1. Animals should only be used for experiments that promise to 
increase knowledge of human systems or diseases affecting those 
systems. In other words, the benefits of the experiment must 
outweigh the costs. If animals must be sacrificed or harmed, the 
experiment must be in the pursuit of greater knowledge. 
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2. All possible steps must be taken to minimize any pain or distress 
the animal may experience.  
3. The researcher must consider all possible alternatives to the use of 
animals as research subjects.  
If these three responsibilities are upheld, animals are acceptable research 
subjects. The general assumption among the research community is that it is 
unethical to use animals profusely or for commonplace research, but that “it is 
immoral not to wisely use all the resources that nature has provided, including 
animals, to gain an understanding of how the brain functions in health and 
disease” (Bear et al., 2007). Animals may, and should, be ethically used in 
scientific research so long as such research eventually leads to an overall greater 
quality of life. 
In summary, scientific research is not only accepted but also encouraged 
as long as the previously outlined ethical guidelines are upheld for human 
research participants and animal research subjects. For the research that cannot 
be completed with human participants, animals are the avenue in which this 
knowledge may be acquired. Although it would be ideal to inflict no harm in the 
pursuit of knowledge, this is not always possible. Every benefit has a cost 
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associated with it. The scientific community has decided that the benefit of 
developing cures for various diseases and disorders outweighs the cost of 
animals’ lives. However, looking at the situation in another light, animals used 
for all types of biomedical research is less than 1% of the number of animals 
killed for food in the United States alone (Bear, Connors, & Paradiso, 2007). By 
using the ethical guidelines for animal research, animal lives are considered and 
animals are only used as research subjects if absolutely necessary. In scientific 
research, limited amounts of animal harm are accepted in exchange for a 




The ethical concerns centered on human and animal research are fairly 
common and have been given far greater attention in other works. I have chosen 
not to delve into the ethical concerns of scientific research because of more 
pointed ethical questions regarding the overarching goal of this thesis, to find a 
treatment for PTSD.  
Before I move into other ethical questions associated with attempts to find 
a treatment for PTSD, it is important to note that all ethical guidelines for animal 
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research were upheld in the study I completed. My study was looking to gain a 
better understanding of the neurochemistry of PTSD and to test propranolol as 
an experimental treatment for PTSD symptoms in rats. Both of these goals were 
accomplished, and the research that I completed would not meet the ethical 
guidelines to test humans. Also in accordance with the responsibilities held by 
the researcher, I did my best to minimize any pain or distress the animals may 
experience. The animals were appropriately nourished and housed, and I did not 
subject any animals to any threatening experiences outside of the experimental 
procedure. Before beginning my experiment, I explored all possible alternatives 
to the use of animals in my study. Given the nature of the topic and the focus of 
my study, I was led to use animals in my study, but did not violate any of the 
aforementioned ethical criteria for conducting research using animals as research 
subjects. 
My study and overall thesis topic sparks questions surrounding the ethics 
of treating PTSD as well as those concerning animal research. On first glance, it 
appears justifiable for an individual suffering from PTSD to want his or her 
premorbid quality of life, meaning the symptoms from PTSD should be treated. 
If a person had a broken leg, he or she would have that leg casted, set back in 
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place, and ultimately corrected. The decision to treat mental injuries, especially 
PTSD, is not quite that simple. The main side effect of prospective 
pharmacological PTSD treatments is either memory loss or the loss of the 
emotional connection to the traumatic memory (Cukor, Spitalnick, Difede, Rizzo, 
& Rothbaum, 2009).  The value of one’s memories and emotions are terribly 
important however. A person is only who he or she is because of his or her 
previous experiences, the memories of those experiences, and how he or she feels 
about those experiences. Altering or fixing one’s mental illness by means of 
memory erasure is quite different than fixing a physical injury because mental 
abilities create the personal identity of the person affected by the injury. Due to 
the value of one’s memories and emotions, the search for a PTSD treatment may 
be complicated by whether or not a person is willing to forget one of his or her 
life’s most influential experiences. In other words, if one’s memory of, or the 
emotional connection to, the experience must go, is it still best for the PTSD 
victim to be pharmacologically treated? Conversely, is there a value in enduring 
and working though suffering, via therapy options, to alter one’s attitude about 
the trauma and overcome one’s symptoms without taking a drug?  
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If it is decided that it is best to pharmacologically treat the patient, another 
question is raised. Who do you treat and when? In addition to memory loss, 
many of these drugs and treatment strategies must be administered either before 
or immediately following the trauma. If a drug must be administered before or 
immediately following the trauma, how does one choose who does and does not 
receive the treatment? What scenarios would qualify a person for this type of 
preventative treatment? If a drug were to be administered post-trauma, a person 
would need to be able to give informed consent, which could present another 
issue with administration. After a traumatic experience, a person may not be in 
the state of mind necessary to give informed consent to the physicians. Although 
it seems simple at first glance, there are many questions that must be answered 
and ethical concerns that must be explored before a treatment for PTSD may be 
brought to the public.  
The first question to concentrate on is the cost of a treatment for PTSD and 
the potential value of suffering. In the study that I completed, I did not see an 
effect of propranolol on all PTSD symptoms. Although this research did not 
support the hypothesis I set out to address, I am not entirely certain that this 
failure to find a consistent working treatment for PTSD disadvantages PTSD 
PROPRANOLOL AND PTSD 
 
- 63 - 
 
victims or society. Although it may be crystal clear to many people that PTSD 
victims need a drug rather than a therapy, I am not certain that is the case. Before 
I proceed further with this line of thought, I must say that I do not have a 
personal connection to anyone with PTSD, and I am not attempting to speak as if 
I do have such a connection. Clearly, the types of traumas that dispose an 
individual to the suffering characterized by PTSD are horrific. I also can attempt 
to understand the difficulties that a PTSD victim suffers on a daily basis. Yet, I 
am uncertain that a pharmacological treatment for the disorder is the correct 
answer to the problem.  
The most promising treatments for the 5.2 million Americans suffering 
from PTSD are memory attenuating drugs.  These drugs, one of which is 
propranolol, have shown limited evidence that PTSD symptoms can be reduced 
due to the numbing of emotions involved with the memory (Henry, Fishman, & 
Youngner, 2007). However there is also some concern that such drugs may lead 
to complete memory loss for a period of time (President’s Council on Bioethics, 
2003). As a result, the value of emotions and memories has been brought into the 
discussion of PTSD treatment. If an individual loses his or her emotional 
connections to a memory or loses the memory completely, there may be legal 
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implications. In addition to these topics, it is important to consider the lessons an 
individual learns as a result of a trauma and how these lessons further 
complicate whether or not one’s memories should be altered in an attempt to 
treat PTSD symptoms.  
It is important to consider the moral costs that may accompany a 
pharmacological treatment for PTSD. A PTSD-eliminating drug has many 
repercussions for the victim concerning life after the trauma. The opposition for 
pharmacologically treating PTSD leads me to question how an effort to help a 
PTSD victim may transform into harming the individual and, in turn, society by 
the removal of that individual’s connection to the experience. If every victim of a 
trauma were to alter his or her memory of the event, it the overall impression of 
the trauma would be altered as well. In order to answer this question, I believe 
one must explore the value of suffering while remaining conscious to the fact 
that 5.2 million Americans are currently suffering from an event that has already 
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II. What is the value of suffering? 
Before attempting to find value in suffering, it is necessary to establish an 
understanding of what I mean by suffering. Although a person may be said to 
suffer a broken arm or a sprained ankle, physical pain is not typically what 
someone is referring to when he or she says that there is suffering all over the 
world. There is a difference between being hurt and suffering. A physical pain 
may hurt, but for suffering to result from an experience a psychological pain 
must exist as well. Physical hurt and suffering are connected, but separate 
phenomena. As I use the term, suffering does not reference physical pain in itself, 
but psychological traumas that result from biological malfunctions within the 
brain. Suffering is a recently orphaned child whose parents were slaughtered 
during a robbery. It is the pain of the people affected by genocide and a 
wounded veteran trying to forget the travesties of war. Suffering also ensues 
after the loss of a loved one or the permanent loss of one’s physical capabilities. 
Although one may physically see the sorrow and distress brought on by the 
suffering, suffering itself resides within the mind. Suffering results from feelings 
of depletion, loss of meaningfulness, and lack of identity. Although these 
examples may detail a physical pain, they also deal with a certain type of 
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psychological hardship. The newly orphaned child is forced to deal with feelings 
of loneliness, helplessness, and abandonment. Likewise, a population affected by 
genocide must deal with thoughts of powerlessness and the war veteran must 
overcome the evils witnessed in war. Losing a loved one or a person’s ability to 
function completely alters the life of the individual, and he or she is forced to 
recreate his or her identity and meaning in life. In generalized, more abstract 
terms, suffering is the form that a memory takes when it is charged with negative 
emotion.  
All people suffer to some degree, but the type of suffering that is endured 
by PTSD victims is the result of biological malfunctions that cause a single 
moment in time to be relived unconsciously and uncontrollably. A desire of the 
body is to maintain equilibrium. The body attempts to avoid the emotional 
charging of negative emotions and minimize suffering. The human mind 
attempts to maintain equilibrium between memory and oblivion and rejects 
irrelevant or disruptive memories (Evers, 2007). The extensive amounts of stress 
hormones released at the time of a traumatic event lead to an inability to reject 
the memory, and subsequently give rise to a powerful memory which 
continually replays in the individual’s head (Heim & Nemeroff, 2009). At this 
point, PTSD develops and suffering ensues. PTSD is a severe form of suffering, 
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and due to this severity, the initial response is that the suffering must be treated 
in a way that returns the victim to his or her pre-morbid style of living. After all, 
since PTSD is detrimental and results from biological malfunctions, a drug 
should be developed to correct those malfunctions, right?  
The degree of dysfunction that suffering can cause for those suffering 
from its most severe forms makes it important to attempt to find value in 
suffering. Suffering causes a great deal of psychological pain and in many cases, 
physical pain as well. For instance, consider an example of human suffering that 
Fyodor Dostoyevsky outlines through the words of Ivan in Book V of The 
Brothers Karamazov:  
Imagine a trembling mother with her baby in her arms, a circle of 
invading Turks around her… pet the baby, laugh to make it laugh. They 
succeed; the baby laughs. At that moment, a Turk points a pistol four 
inches from the baby’s face. The baby laughs with glee, holds out its little 
hands to the pistol, and he pulls the trigger in the baby’s face and blows 
out its brains (1880).  
The imagery of this scene evokes sorrow for the naïve child, but attempt to 
imagine the heart-break that the mother must feel and the subsequent suffering 
that will surely ensue. Furthermore, attempt to imagine living with that memory 
constantly replaying in your mind for the rest of your life. These situations 
support the desire to eliminate suffering. A single case of PTSD and the 
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experiences leading up to this psychological trauma cause any observer to ask: 
who deserves this? No person deserves to suffer in this manner, but suffering 
remains a part of daily life due to the free will of humankind. With free will, evil 
is a part of the human condition, and due to this evil suffering enters into the 
world. Since evil continues to exist, the goal is to overcome suffering and to find 
value in life in the midst of suffering. Alone there is no value in suffering. No 
person can honestly claim that there is value in a mother watching her child be 
executed in front of her eyes. However, there is value in the process of 
overcoming suffering by addressing the traumatic experience and attempting to 
move forward to find meaning as a result of that experience.  
While free will allows suffering to enter into the world, it also allows for 
pleasure, love, and positivity. In Man’s Search for Meaning, Dr. Viktor Frankl 
exhibits how free will can lead to drastically different outcomes. Frankl states, 
“Man is that being who invented the gas chambers of Aushwitz; however, he is 
also that being who entered those gas chambers upright, with the Lord’s Prayer 
or the Shema Yisrael on his lips” (1985, p.157). Free will allows for suffering, but 
it also provides an individual the option of offering love to a fallen war veteran 
or a woman who was not given a choice. Free will allows an individual to show 
love to those who are suffering and to have a voice in advocating a treatment for 
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disorders such as PTSD. Through free will a person has the choice to react to 
each experience as he or she wishes. With the freedom of choice comes the 
freedom of opportunity, both good and bad. Freedom may lead to suffering, but 
it also provides the opportunity to rush toward meaning. 
Through free will, a person is provided the opportunity to react to each 
scenario in the way that he or she chooses. There are two methods by which a 
victim may choose to move past the reliving of traumatic memories. One way is 
to mitigate suffering with a pharmacological treatment, such as propranolol. 
Through such a treatment, a person may never develop the traumatic memories 
that perpetuate suffering. Another option is to work through one’s suffering 
rather than taking a drug, and realizing that the trauma is now in the past, that 
each day is a brand new day, and that there is meaning in the life that still lies 
ahead. In other words, one may work to overcome his or her suffering to find 
meaning. 
Overcoming suffering without a treatment is tough but not impossible. 
What does it mean to overcome suffering? Overcoming suffering means 
recognizing that a trauma occurred, understanding that there is suffering 
attached to that trauma, and realizing that one can reduce his or her suffering by 
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changing his or her relationship with the traumatic experience. While this is 
easier said than done, it can be realized. No trauma victim is in this process 
alone, and needs to utilize his or her support system to help get him or her 
through this tough time. In addition to family support, individuals may look for 
therapeutic help.  
The three most common therapy treatment methods for PTSD are 
cognitive behavior therapy, eye movement desensitization and reprocessing 
(EMDR), and stress management (Ponniah & Hollon, 2009). Trauma-focused 
cognitive behavior therapy involves repeated exposure to the traumatic memory 
through cognitive methods and then progressively changing the individual’s 
thought processes and behaviors towards the trauma. EMDR utilizes dual 
attention tasks to help the patient process the traumatic event. EMDR involves 
the patient focusing on negative trauma-related memories while engaging in a 
task involving some form of bilateral stimulation, such as eye movements, until 
distress has decreased and belief in more positive trauma-related thoughts has 
increased. Stress management does not focus on the trauma, but involves the 
patient’s learning skills to help manage anxiety. Such skills consist of slow, 
abdominal breathing, relaxation techniques, learning to use positive statements 
and self-talk strategies, distraction techniques, and assertiveness training. 
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Therapies such as these help trauma victims manage and eventually overcome 
their suffering. Once suffering is overcome, meaning may be found in the 
individual’s renewed appreciation for life absent of suffering. 
Despite the intentions of these therapeutic treatments, the efficacy of these 
therapies is not ideal. Although these therapies prove helpful for some patients 
suffering from PTSD, 30% of patients who develop PTSD will still be suffering 
from treatment ten years following the trauma (Langevin, De Salles, Kosoyan, & 
Krahl, 2010, p. 1241). These individuals may not have received therapy or 
followed through with their therapy, but regardless, 30% is a large number of 
PTSD victims with chronic symptoms. For this reason, current research 
surrounding prevention strategies for PTSD has concentrated its efforts on 
pharmacological treatments. 
 The goal of a preventative pharmacological treatment is to alter one’s 
memories, effectively inhibiting PTSD symptoms. Researchers and physicians are 
looking at experimental drugs that may numb the emotions associated with a 
patient’s memories or perhaps eliminate recollection of the traumatic memory 
entirely. It is not practical to erase a patient’s past memories. However, 
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eliminating a group of memories that relate to a tormenting period of a patient’s 
life is not out of the question.  
Research has progressed in identifying potential drugs that may be 
utilized as preventative PTSD treatments. Over the past decade, corticosteroids, 
beta-adrenergic antagonists (propranolol), and opiate analgesics (morphine) 
have been shown to reduce hormonally enhanced memories and fear 
conditioning (Cohen et al., 2010). Other drugs such as D-cycloserine, a NMDA 
receptor agonist, Ketamine, an NMDA receptor antagonist, Praosin, an alpha-1 
adrenergic receptor antagonist, and Ecstacy have all shown promise in 
selectively altering individual’s memories and reducing PTSD symptom severity. 
The discovery of a drug that would allow people who experience a 
traumatic event to continue on with their lives rather than develop PTSD would 
be a great finding. With such a treatment, there may be a way for the mother, 
who saw her baby executed at point blank, to have peace of mind. Although this 
does not completely eliminate traumatic events, it does eliminate the day to day 
struggles that a person may face as a result of such events. If the mother does not 
remember seeing her baby taken from her, she is much less likely to suffer. In 
much the same way, a war veteran with PTSD may finally be able to sleep 
through the night without revisiting Vietnam.  To rid an individual of his or her 
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suffering is to give the individual a renewed quality of life. Clearly, such a 
treatment has great potential for improving the lives of many.  
The benefits of eliminating suffering are evident, but there are also 
arguments warning against such action. Whether one’s memories are 
excruciating, glorious, or both, experience is what shapes who an individual 
becomes and how that individual derives meaning from life. Suffering is only 
known as a result of the knowledge and memories of the way things were before 
a certain traumatic event. Each individual is who he or she is, at this moment, 
because of his or her memories of the experiences that he or she has encountered.   
Memory has a tremendous value regarding who we are as human beings. 
In The Use and Abuse of History, Nietzsche speaks of history, or memory, and 
proceeds to pose a question. Nietzsche asks if you would rather live as a cow 
simply living in the moment feeding on hay or as you are with all your thoughts, 
worries, and concerns. According to Nietzsche, man envies the “beast’s 
happiness,” but would never change places with the beast (1874). Nietzsche 
suggests that memories are worth the cost of unhappiness because there is value 
in knowledge of the past, and this knowledge adds depth to each person.  
A major criticism of a possible PTSD treatment is that it may eliminate a 
crucial memory to the individual’s life. Nietzsche is also quick to point out that 
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forgetting helps make a person who he or she is along with memories. Some 
things in life must not be remembered. The true question is which memories 
should be remembered and which ones forgotten. It may be argued that if a 
memory is going to be forgotten, why not a painful memory? Yet it may be 
argued just as strongly that a traumatic memory affects an individual the way it 
does for a greater reason. Should an individual eliminate a memory that will 
have a truly profound impact on his or her life, even if there may be potential 
suffering as a result of that memory? For the majority of PTSD victims, I believe 
that the experience should be worked through because meaning can be derived 
from the experience. However, if a person believes that he or she cannot live with 
his or her suffering, it may be best for that person to eliminate the traumatic 
memory. There is no value in suffering alone. The value associated with 
suffering is found through the transformation of one’s outlook on life and the 
discovery of meaning.  
The other mechanism through which a PTSD treatment may work is by 
numbing the emotional impacts of a memory. Opposition to this approach 
surrounds the idea that one’s emotions are intimately linked to his or her outlook 
on the world. Hurley (2007) explains that emotions are often seen as an 
individual’s understanding of his or her circumstances. For instance, a person 
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may be afraid because there is an immediate threat. Additionally, emotions serve 
evaluative purposes. Emotions show the values that a person holds, but they are 
also able to change based on the circumstances of the situation. For example, a 
mother may show compassion to her son struggling with PTSD after returning 
home from war. Emotions serve vital purposes in human lives.  
The elimination of one memory’s emotional associations would not 
contribute to personal change in the same way as the erasing of an entire 
memory would, but it would change the relationship to a traumatic event. For 
example, if a rape victim was treated with propranolol immediately following 
being raped, and did not have any emotional connection to the incident, she 
might not be able to realize fully the horror of the event that happened to her. 
She may know that rape is a terrible act because she has been told so, but she 
may not know this personally due to her lack of a negative emotional experience 
to being raped. If she was raped and did not have an adverse reaction to the 
event, the general opinion that rape is bad may be challenged by the individual’s 
lack of emotions related to the experience. The loss of one emotional connection 
may not greatly influence society, but the cumulative loss of all the emotional 
connections of all the traumatic experiences of all victims with PTSD would have 
a profound effect on society. Using the same example, if no rape victim had a 
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negative emotional connection to the event because each rape victim was given a 
memory altering drug to repress the effects of the sexual event, rape may not be 
viewed as such an evil act. Emotions play a major role in humans’ lives and are 
as crucial as memories to an individual’s identity.  
The answer to overcoming suffering does not lie in eliminating the 
memory of the trauma or preventing a memory from developing, but in deriving 
meaning from the events that have occurred and altering one’s relationship with 
the traumatic event. Suffering is the form that a memory takes when it is 
extremely charged with negative emotion. One’s memories play a huge role in 
suffering. It is impossible to eliminate or even lessen suffering unless one is 
willing to alter the relationship one has to his or her memories. It is one’s 
memory that provides a reference for what does and does not cause suffering. 
Memories of good and bad times, and feelings of disappointment, anger, 
suffering, or any other emotion are only understood because of previous 
experiences. In addition to providing a reference point, memory provides the 
narrative that continually influences suffering. As long as one maintains a 
negative relationship with the event that caused his or her suffering, the 
suffering has potential to exist in a harmful way. However, the negative 
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relationship does not have to exist forever. It is possible for a person to alter his 
or her attitude about a traumatic experience.  
When an individual is able to live through the suffering of remembering a 
trauma and alter his or her attitude about a traumatic experience, posttraumatic 
growth occurs. Positive posttraumatic growth often co-occurs with PTSD (Levy 
& Clark, 2008). Although many people disregard the possibility of posttraumatic 
growth, the idea that tragedy can trigger personal transformation is an ancient 
thought occurring throughout the course of major religions, Greek tragedy, and 
other literatures (Tedeschi & McNally, 2011). Typically there are five domains in 
which trauma may elicit personal growth: renewed appreciation for life, new 
possibilities, enhanced personal strength, improved relationships with others, 
and spiritual change (Tedeschi & McNally, 2011). An example of posttraumatic 
growth is found in a study performed by Sledge, Boydstun, & Rabe (1980). This 
study interviewed aviators that were shot down, imprisoned, and tortured for 
years by the North Vietnamese, and of those interviewed, 61.1% reported that 
they had benefited psychologically from the experience. Among the reports, the 
aviators said that imprisonment had produced positive changes in their 
personalities, increased their self-confidence, and taught them what was truly 
important in life (Tedeschi & McNally, 2011). It is true that certain variables 
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mediate posttraumatic growth, but it is a real possibility for anyone suffering 
from a traumatic experience. Furthermore, it is even more promising for PTSD 
victims that symptom severity is positively correlated with the degree of 
posttraumatic growth. A preventative, pharmacological treatment for PTSD 
would eliminate any chance for posttraumatic growth or personal change 
because the traumatic event would not have a great impact on the victim’s life.  
Posttraumatic growth is another life altering effect of the trauma that would be 
prevented from developing along with the memory of the experience or the 
emotions involved. Perhaps PTSD is not a biological malfunction but a 
purposeful occurrence. Through dealing with one’s trauma and suffering in an 
open, honest manner, an individual can experience posttraumatic growth and 
find meaning in his or her life after the trauma. 
Although it is true that humans are subject to biological, psychological, 
and sociological conditions, certain feats are unexplainable. It is possible for an 
individual to live through unimaginable suffering, even if completely 
undeserved. In Frankl’s Man’s Search for Meaning, Nietzsche is quoted as saying, 
“He who has a why to live for can bear with almost any how” (Frankl, 1985). It 
may be unexplainable, but any individual can live through any amount of 
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psychological suffering as long as he or she has the will to do so, which is 
illustrated through research on posttraumatic growth. 
In respect to the values of memories and emotions as well as the 
possibility of posttraumatic growth, it may be that the argument for the 
elimination of suffering is not as simple as originally thought. The question 
quickly evolves from a purely scientific one regarding the definition and 
treatment of suffering to a question fully invested in the essence of whom the 
patient is and his or her meaning in life. Before a person can begin to 
contemplate a treatment for suffering, he or she must decide what he or she 
believes his or her experiences are worth. Is it best to eliminate one’s pain or fully 
invest in the experience and work to overcome the suffering that accompanies 
the traumatic memory? 
It is entirely possible to derive value from suffering, and suffering does 
not have to be eliminated in order to find meaning post trauma. It is important 
for an individual to live through his or her suffering because each individual has 
a say in what he or she will become and the changes that he or she can influence. 
After all, “A human being is not one thing among others; things determine each 
other, but man is ultimately self-determining. What he becomes—within the 
limits of endowment and environment—he has made out of himself” (Frankl, 
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1985). Regardless of what today holds, tomorrow is a new day with new 
opportunities. A man has the choice to behave like a “swine” or a “saint.” The 
individual can either choose to sit by thinking about the past or live in the 
present and push beyond the suffering to find meaning. The search for meaning 
may be accomplished by avoiding suffering through a pharmacological 
treatment. However, by intentionally focusing on experience and intentionally 
working through the hardships, the search for meaning becomes so much more 
informed. This choice is the individual’s to make. In the case of PTSD, the victim 
may choose to numb his or her memories by accepting treatment or he or she 
may deny pharmacological treatment and seek to find meaning in life after the 
trauma.  
The ability to use one’s suffering to find meaning is predicated on one’s 
attitude. If it is not possible for a person to find a reason to overcome his or her 
suffering, it is nearly impossible for him or her to see any meaning that will 
result from such suffering (Frankl, 1985). In this case, the PTSD victim most 
definitely should accept treatment and proceed on with his or her life because 
there is no value in suffering by itself. However, if the victim believes that he or 
she may find meaning in life after the trauma, then a treatment may not be 
necessary.  Frankl explains, “The way in which a man accepts his fate and all the 
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suffering it entails, the way in which he takes up his cross, gives him ample 
opportunity—even under the most difficult circumstances—to add a deeper 
meaning to his life” (1985). Frankl suggests that suffering provides an individual 
the unique opportunity to find meaning in life, and through the discovery of 
one’s meaning he or she is able to alter his or her relationship with the traumatic 
memory.  Life is not special in itself, but living for a meaning and having the 
ability to live for a purpose is special. Although it is difficult to see initially, 
suffering may influence a new meaning in life and a new purpose of living.  
Through the discovery of meaning, a victim is able to alter his or her 
relationship with a traumatic memory and use his or her suffering as fuel for the 
good that may lie ahead. It is quite difficult to see how a mother’s viewing of her 
child’s death can be turned into human achievement or how a war veteran may 
be able to transform his actions of killing in Vietnam into personal growth, but 
these instances do exist. Frankl makes this clear when he says, “even the helpless 
victim of a hopeless situation, facing a fate he cannot change, may rise above 
himself, may grow beyond himself, and by so doing change himself. He may 
turn a personal tragedy into a triumph” (1985). No matter the scenario, an 
individual has the opportunity to alter his or her attitude about the situation. For 
example, due to her child’s death, the mother previously mentioned may wish to 
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adopt an orphaned child. In doing so, the mother would provide the orphan 
with a home and a nurturing upbringing so that he or she is aware of the justices 
and the injustices of the world. Likewise, the war veteran may be able to speak as 
an advocate to young men and women on the value of a life and in doing so, 
save the lives of others. It is truly difficult to overcome suffering, but if one can 
look at the future ahead rather than the events of the past, he or she may find 
meaning in life and alter this or her relationship with the traumatic memory.  
Any event has the power to be transformative, and every experience 
contributes to who you are as a human being. The events that cause PTSD or 
other degrees of suffering are extremely powerful due to the emotional nature of 
the event. Perhaps this leads an individual to think that these events must be 
eliminated from one’s memory. Still one may choose to use these events as 
powerful tools to make a personal change and create meaning.  The greatest 
amounts of suffering have the potential to lead to the greatest degrees of 
posttraumatic growth, but this is only possible if one is willing to look past his or 
her suffering, alter his or her relationship with the traumatic event, and 
ultimately find meaning. If one is able to maintain the attitude necessary to find 
meaning, then there is most definitely value to the process of working through 
and overcoming the suffering that results from a traumatic event. 
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Through hard work and a commitment to life, I believe that any 
individual has the ability to overcome suffering and find meaning in life. 
Research shows that approximately 60% of people suffering from PTSD show 
evidence of posttraumatic growth, and that the degree of posttraumatic growth 
is positively correlated with the severity of PTSD symptoms (Tedeschi & 
McNally, 2011). This finding illustrates that it is possible to find a meaning in life 
and a reason for living, in the midst of the suffering that may ensue. The 
previous section’s analyses support that there is value in suffering alone but that 
there is tremendous value in overcoming suffering by way of dealing with one’s 
current state and working to improve one’s self on a daily basis. For those who 
are committed to dealing with their suffering in a real, honest, and upfront 
manner, there is an opportunity to grow from any experience and find meaning.  
Although I believe everyone can find meaning beyond trauma and 
suffering, I also realize that some individuals need more help than others in 
finding meaning. If it is true that every person has the ability to grow from any 
experience, why do only 60% of PTSD victims show evidence of posttraumatic 
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growth? What about the other 40%? I believe that some individuals need help in 
their search for meaning. Some individuals suffer to such an extent that they 
cannot complete effortless, daily tasks or muster enough courage to simply go to 
bed at night. How are these individuals supposed to find meaning in such a 
broken life? These are the types of patients that need help to carry on; these 
individuals need a treatment to get them back into living life. Although current 
drugs threaten the victim’s memories and emotions, for these particular 
individuals the costs associated with the drug may be outweighed by the chance 
of the victim returning to a version of their premorbid functioning. 
Subsequently, a return to daily functioning may allow the individual to partake 
in activities that lead to the discovery of meaning in one’s life that was inhibited 
by PTSD. In certain circumstances, I believe that a treatment for PTSD is needed 
in order for the victim to have the ability to move past his or her suffering and 
redeem his or her memory of the trauma. 
The possibility of treating PTSD, as well as other mental disorders, 
ultimately relies on the victim’s situation and decision of whether or not he or 
she can live an agreeable life without a treatment. If a person truly believes that 
he or she will not be able to function, and he or she is willing to lose the 
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memories or emotional connections to the trauma involved, I do not believe that 
a person should be denied a treatment if one is available. Treatment for PTSD 
should be considered on a case by case basis due to the high stakes for those 
wishing to pursue a treatment strategy.  Patients should be made aware of the 
possibilities of recovery without a treatment. It remains true that growth can be 
obtained for most PTSD cases without a pharmaceutical treatment. Yet, certain 
cases of PTSD are so inhibiting that they disallow the patient to live his or her 
life. Regardless of these patients’ knowledge of potential side effects and the 
wider implications of these effects on society as a whole, if a treatment for PTSD 
is made available for those victims who cannot even sleep at night because their 
traumatic experience haunts their dreams, it can be expected that these 
individuals will choose the treatment option despite the individual and societal 
costs.  
While uncertain that this scenario will occur due to ethical considerations, 
if there is enough pressure and a growing market for a PTSD, or suffering, drug 
to be developed, I believe that it is likely that a PTSD drug may become 
available. In preparation for this possible scenario, it is important for people to 
give serious consideration to how such a treatment could be implemented. 
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Although this drug may be intended for those victims with incredibly severe 
versions of PTSD, it is likely that treatment will become universally available for 
all persons affected by PTSD.  
Whether the treatment for PTSD were to become universal or simply 
remain available to those suffering from the most severe cases of PTSD, there are 
issues regarding how such a treatment could be implemented. For instance, for 
such a treatment to be implemented the patient would need to be able to give 
informed consent. This would be quite difficult seeing that the majority of 
experimental treatments for PTSD would need to be used within a certain time 
frame following the trauma. Because most individuals who go on to develop 
PTSD do not have the mental aptitude to give informed consent, the possibility 
of treatment is complicated even further. There are many concerns surrounding 
potential implementation strategies for preventative as well as reactive 
treatments for PTSD.  
While I believe that a PTSD drug is far from market, I realize that certain 
people need a treatment in order to move on with their lives. Once need becomes 
too large for society to ignore, a treatment for PTSD is likely to be given more 
attention. Before this occurs, it is important to be proactive and call attention to 
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the possible complications concerning the implementation of a PTSD medication. 
In the following section, I will provide an overview of the possible issues about 
PTSD treatment implementation as well as a hypothesis of how a PTSD 
treatment may be implemented justly. 
 
III. How could a treatment for PTSD be implemented                
ethically and justly? 
 
It may be true that science is far from curing PTSD, but it may also be true 
that society is close to seeing a treatment for PTSD on the market. It is yet to be 
seen when or if a treatment for PTSD will be developed and implemented. 
However, it is never too early to think how a drug may be implemented and how 
the implementation of that drug may affect society. If one believes that he or she 
cannot function without medication or that the reclaiming of their previous life is 
greater than the cost of losing one’s memory, a PTSD treatment may be 
developed to diminish or eliminate PTSD symptoms when the drug is given 
immediately after the trauma. Such a drug could potentially alleviate suffering 
for millions of individuals.  This sort of treatment has ethical concerns due in 
part to the potential inability to give informed consent. A solution to this ethical 
dilemma may be to provide a preventative rather than reactive drug for PTSD. If 
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you could give each individual about to enter a potentially traumatic 
environment or situation a drug which would prevent any chance of the 
development of PTSD, PTSD would cease to be an issue. However, this 
implementation strategy also has widespread ethical concerns. For instance, how 
does one decide which individuals receive the treatment? What constitutes a 
traumatic environment or situation? How would a preventative treatment for PTSD 
affect society? These are important questions to consider and the aim of this 
section. I believe that there are individuals in absolute need of a treatment for 
PTSD. However, I do not think there is a foolproof process of implementation for 
such a treatment. 
Theoretically, the prevention of PTSD may be accomplished either by 
providing a treatment prior to the trauma or by providing a treatment in 
response to a traumatic event. Henry et al. (2007) reports that the strength of a 
memory is directly correlated with the release of endogenous hormones such as 
adrenaline. During a stressful situation, an over-release of adrenaline occurs and 
this results in elevated levels of noradrenaline. This elevated level is what is 
thought to perpetuate the over consolidation of the memory and cause PTSD 
(Henry et al., 2007). If a treatment, such as a beta-adrenergic antagonist, is used 
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to prevent this process of over-consolidation from occurring, the enhanced 
memory as well as the PTSD symptoms may be eliminated. Thus, it is thought 
that a preemptive attempt to treat PTSD would be the most effective. Following 
this line of thought, several studies have successfully prevented the development 
of PTSD by administering a preventative treatment before subjecting the subject 
to the experimental trauma (Cahill et al., 2002; Maheu et al., 2005; Reist et al., 
2001; van Stegeren et al., 2005).  
Strictly looking at the neurological mechanisms through which it is 
believed that PTSD results, it seems that treatments for PTSD should be 
preventative in nature. Yet, in a social context, this conclusion is not so easily 
reached. If a treatment is given prior to a traumatic experience, it must be known 
that there is a good chance that a traumatic event will occur. In the case of many 
traumatic events, such as natural disasters and car accidents, this knowledge is 
unavailable. Yet in certain circumstances, it may be concluded that a traumatic 
event is likely to occur. Individuals in the fire, law enforcement, military, and 
rescue fields may benefit from a preventative treatment of PTSD because these 
professions typically increase the probability of being exposed to a traumatic 
event. Individuals such as these may be treated with short-term memory 
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suppressors prior to entering a situation that could potentially put them at risk 
for developing PTSD. This initially sounds like a fantastic option, but one must 
remember that any current PTSD treatment either blunts the victims’ memories 
or the emotions involved with those memories. These remain to be huge side 
effects not to be taken lightly. Additionally, both short and long term side effects 
of repeated usage of such a drug remain unknown. 
 Although a preventative treatment for PTSD may be most effective, it 
may not be the most advantageous treatment strategy. If one attempts to reduce 
suffering through preemptive intervention, many questions arise. First, how do 
you decide who receives a preventive PTSD treatment? What are the criteria for 
being eligible for such a treatment? Perhaps you only administer such a 
treatment to individuals whose jobs entail regular exposure to traumatic 
experiences. If this is the case, how do you decide what regular exposure to 
traumatic experiences means? Because of the importance of memories to an 
individual and society, a line must be drawn so that the elimination of memory, 
whether traumatic or not, is not as accessible as the elimination of a headache.  
In addition to the unsolved questions regarding implementation, the 
preventive strategy to treating PTSD may have wide ranging impacts on society. 
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If large groups of people are treated for PTSD, they will not suffer as much. They 
also may not remember the events that occurred or their emotional feelings 
about those events. Since the people who may be treated pre trauma are the 
individuals in rescue, protection, and law enforcement roles, these side effects 
may create huge consequences for society. For example, in the court of law, these 
individuals often have to give testimony, but this could not be justly achieved if 
their memory of the situation had been impaired in any way. This problem 
would become much larger if this form of PTSD treatment was made available to 
a wider group of people. A preemptive treatment strategy for PTSD does not 
only have implementation issues but may negatively impact society as well.  
The other viable option for treating PTSD, as previously mentioned, is to 
do so after the traumatic event has occurred. This treatment also aims to reduce 
the amount of noradrenaline produced in response to stress. Although providing 
treatment post stress is less effective in reducing the consolidation of memory, it 
still has memory blunting effects and may be an effective strategy for treating 
PTSD. Treating PTSD victims post trauma removes much of the issue of 
determining who should and should not be treated. For instance, with this 
treatment strategy, not every firefighter, police officer, or soldier would be given 
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a memory repressing drug. Instead, only those that have been exposed to an 
excruciating trauma or wish to receive the treatment after the trauma would be 
given the drug. This strategy would reduce the amount of emotionally blunted 
memories. Thus, the impact on society would not be as great, and the 
implications of PTSD treatment outside that of the victim’s life are not 
controversial. 
A post trauma PTSD prevention strategy must be advantageous for the 
individual in order to be implemented. At the conclusion of section III, I 
concluded that the majority of PTSD victims grow from the traumatic experience 
causing their PTSD symptoms but that some individuals do not show any 
posttraumatic growth and require a PTSD treatment in order to determine 
meaning from their traumatic experience. It is not possible to reduce the 
consolidation of memory years after the trauma has occurred. In order to reduce 
PTSD symptoms, the treatment must be administered either prior to or 
immediately following the traumatic experience. Thus, a reactive treatment to a 
traumatic event does not allow the individual the opportunity to respond to the 
event either positively or negatively. Unlike a preventative treatment, the post 
trauma treatment strategy does still allow the victim or those connected to the 
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victim to determine how severe the traumatic experience has been and if the 
victim should be given a memory repressing treatment. Although there is no 
sure fire method of determining if a person will develop PTSD in isolation or in 
combination with posttraumatic growth, with the reactive treatment strategy, 
each victim has the ability to choose whether or not to receive treatment.  
A reactive PTSD treatment strategy thus limits the impacts of a PTSD 
treatment on society while allowing for an individual to choose whether to 
endure the suffering and traumatic memory or to administer a PTSD symptom 
reducing treatment. This is not to say that this strategy is without concern. Like 
the preemptive PTSD treatment strategy, the reactive PTSD treatment strategy 
has an issue with implementation, informed consent. Following a traumatic 
experience, especially one that results in the most severe forms of PTSD, the 
victim is not likely to be in any emotional state to give informed consent. This 
inability of a victim to give informed consent is a major hesitation in the 
treatment of PTSD.  
Informed consent is the medical avenue through which a treatment may 
be made available to a patient. However, informed consent requires the patient 
to decide what his or her best option is. Does the patient wish to be treated or 
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not? Supady, Voelkel, Witzel, Gubka, and Northoff (2011) state that decision 
making is the crucial psychological process in informed consent. The United 
States, as well as other Western countries, adheres to a mandatory model of 
autonomy. This means that patients have the right to make informed choices for 
themselves. The traditional, paternalistic model of medical decision making 
differs from the autonomous model by mandating doctors to choose which 
option is most advantageous for the patient. According to this view, patients are 
cognitively and emotionally unprepared to make decisions in their best interest 
(Botti, Orfali, & Iyengar, 2009). Although United State’s doctors still take the 
Hippocratic Oath to “follow that system of regimen which, according to my 
ability and judgment, I consider for the benefit of my patients,” it has been 
decided that patient’s values should also be given greater value than the 
knowledge of the medical staff (Oath of Hippocrates, ca. 400 BC/1910). This is in 
large part due to the Kantian philosophy that people are not merely a means, but 
an end in themselves. A doctor may aid in the decision process, but ultimately, 
the decision is not the doctor’s to make. Thus, the mandatory model of autonomy 
presupposes that patients know their risk aversion and desired quality of life 
better than doctors. Individuals must make educated, informed decisions. This 
may be accomplished with the help of doctors’ advice, but a patient must also 
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reflect on his or her own values and decide whether or not to take a treatment. If 
the patient is not in a position to make this decision, it is up to the patient’s 
family or the doctor to make this tough decision. 
Although the paternalistic model of medical decision making has 
technically departed from medical practice in the United States, glimmers of it 
still exist. Doctors still have a great impact on their patients’ decisions. There are 
a few doctors who choose to give patients, and their families, the best available 
data, untainted by the doctor’s perspective, in order to let the family and patient 
determine the best option as it fits with their value system. Most doctors, realize 
that complex decisions are emotionally taxing, and the patient may not be 
prepared to fully make the decision. Ubel and Loewnestein (1997) recap an area 
of cognitive psychology research that has shown that people are rapidly 
overwhelmed by having to consider more than a few options, and quickly resort 
to simplifying strategies that ignore pieces of the information. For this reason, 
many doctors choose to provide their professional perspective on the possible 
options at hand. Hopefully, through this unbiased medical advice, the family can 
make an educated decision in determining if the patient should or should not 
receive the treatment.  
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It is important for the doctor to remain emotionally detached from the 
patient’s available options, but it is also important for the doctor to provide 
information concerning all possible future outcomes in addition to his or her 
medical advice to the patient and the patient’s family. I believe that a PTSD 
victim can only make an informed decision on whether or not to receive 
treatment if he or she is able to understand all of the options for his or her future. 
This is a difficult concept to grasp, but I believe that the decision to be treated for 
the possible development of PTSD is also difficult. It should not be an easy 
decision to completely eliminate the emotional connections it has on a memory 
or to eliminate the opportunity of growing out of an experience. All in all, 
informed consent should be taken very seriously especially for those individuals 
that are at risk for developing PTSD. I believe that the traumatized individual is 
the only person that has the ability to fully make the decision to administer a 
treatment but also realize that this option is not available for the greatest types of 
traumas.  
In the cases where the traumatized individual is unconscious or 
emotionally unavailable to give informed consent, I believe that it is up to the 
family and friends to make the decision for the victim. In my opinion, the doctor 
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should not be making such a decision. The expression of PTSD is not a life 
threatening illness but a lifestyle altering disorder. It is terrible that some 
individuals perpetually suffer from a traumatic experience, but it is also 
miraculous for individuals to overcome their suffering and experience 
posttraumatic growth through the discovery of meaning. When a doctor is faced 
with the decision of providing a memory repressing drug and altering a patient’s 
remembrance of a major event in his or her life, I hope that the doctor will let life 
take its course rather than imparting his or her own beliefs on the situation. 
The process of treating PTSD is a complicated one. It is not beneficial for 
society to universally provide a memory-repressing drug for all people that may 
develop PTSD. In fact, I believe that a treatment for PTSD symptoms only has the 
potential to be beneficial as long as it leads the individual to personal growth. I 
personally believe that the premature treatment of PTSD symptoms, whether 
prior to or following a trauma, is not the route to develop. I believe that the 
search for meaning and the process of aiding people in dealing with their 
suffering and traumatic memories are the area in which research should be 
focused. Helping the suffering by way of a pharmacological treatment is an 
admirable goal, but the discovery of a pharmacological treatment to reduce 
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PTSD symptoms is not the only way to provide help. The methods in which we 
can help those suffering from PTSD are numerous. A pharmacological treatment 
may be the answer some day, but today there are too many issues and ethical 
concerns to develop a treatment. Some of the questions and concerns regarding 
preventative treatments may be resolved, but I do not believe that society is at a 
place to implement such a treatment. It is important to keep focusing on asking 
the tough questions surrounding the treatment of disorders such as PTSD. 
Without giving thought to the issues at hand, no treatment will ever surface, 
PTSD will continue to remain untreatable, and the 40% of PTSD victims that do 




The past three sections covered a myriad of topics including scientific 
research, animals as research subjects, the value of overcoming human suffering, 
posttraumatic growth, and the implementation of possible PTSD treatments. 
Additionally, I have explored the thoughts of others while sharing what my 
beliefs are regarding the issues. However, I do not believe I have fully integrated 
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the past three sections or conveyed what I believe the next steps are for the 
researchers, medical professionals, victims, and general public in dealing with 
PTSD. In the final section of this afterword, I will address these questions and 
begin to bring this thesis to a close.  
 
IV. What does this all mean, and what is next? 
In For the Time Being, Annie Dillard explains that “to save a life is to save 
the entire world” (2000). This statement may be seen as support for a PTSD 
preventing drug. After all, a pharmacological treatment for PTSD may save the 
quality of life that the trauma victim is used to living. However, this statement 
may also be seen as support for the process of overcoming suffering. Perhaps it is 
not up to a drug, but rather up to the individual and his or her family and 
friends to save a life. It may be that we are all called to help each other while we 
are in need, and if we each can save, or help, a single life, then we will save the 
world.  
After conducting my own research and exploring the ethical questions 
surrounding pharmacological PTSD treatments, I have formed to the opinion 
that a preventative treatment for PTSD should not be made available universally 
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because: 1) there are high costs associated with the altering of traumatic 
memories, 2) there would be tremendous implementation problems in 
administering a preventative drug, and 3) In my opinion, the process of 
overcoming suffering is a vital part of life. I believe that there are way too many 
costs and limitations associated with a preventative treatment of PTSD. 
Additionally, I would rather encourage growth by bettering the therapies 
available than eliminating suffering with a pill. I also believe that the search for a 
pharmacological treatment for PTSD should not completely be abandoned. If a 
drug is someday developed to rid an individual of a single memory of an event 
from years prior, I believe that this is an avenue to treating PTSD without the 
tremendous costs, ethical concerns, and implementation issues. 
Although there are 5.2 million people suffering from PTSD in the United 
Sates alone, and many of these individuals’ symptoms will remain chronic, I 
believe that there is great value in working to change one’s relationship to the 
traumatic experience. Suffering is a common misfortune of the world, no 
individual should be forced to endure it in any shape or form, and it is an 
admirable goal to attempt to rid the world of the memories that influence 
suffering. However, I do not believe the mechanism used to alleviate suffering 
should be a pill that attempts to purge the world from traumatic memories. 
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Suffering serves as a main avenue for the discovery of meaning in life and the 
pursuit of Magis. I believe that God allows free will, and thus suffering. A person 
can only recognize injustice in comparison to justice. Although freedom allows 
us to influence suffering, it also allows us to be Gods hands; “It is up to us, what 
God will see and hear, up to us, what God will do. Humanity is the organ of 
consciousness of the universe…Without our eyes, the Holy One of being would 
be blind” (Dillard, 2000, p.196). While today’s world, and every life in this world, 
is full of suffering and injustice, it can be changed without numbing the effects of 
evil actions or erasing one’s memories. A drug is not needed to eliminate 
suffering.  
My recommendation is to concentrate one’s efforts on improving the 
cognitive and behavioral therapies available to treat PTSD and to concentrate 
pharmacological research efforts on a reactive treatment to PTSD rather than a 
preventative treatment. Currently, the efficacy of therapies used to treat PTSD is 
questionable to say the least. PTSD has a lifetime prevalence of approximately 
6.8% in the United States and a 12 month prevalence of 3.8% (Adamec, Muir, 
Grimes, & Pearcey, 2007). This equates to 5.2 million people suffering from PTSD 
in the United States. Of these 5.2 million people, 30% of them will still be 
suffering from PTSD symptoms 10 years from now, and their symptoms are 
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likely to remain chronic (Langevin, De Salles, Kosoyan, & Krahl, 2010). These 
statistics show that the current treatments of treating PTSD are not effective at 
this time and that greater research on ways to develop therapeutic treatment 
options as pharmacological options should be completed.  
In regards to possible pharmacological treatments, I believe that the area 
of focus needs to be on reactive treatments for PTSD. Such a treatment would 
lessen PTSD symptoms, even years after the trauma has occurred. This may seem 
like a fairytale treatment, but this is where the research has begun to shift. 
Research has attempted to single in on how long-term memory is stored, and the 
claim has been made that PKM-zeta is a crucial protein kinase in this process 
(Lisman, 2012). Furthermore, research has shown that the inhibition of this 
kinase, with ZIP, which is a membrane permeable peptide inhibitor of PKM-zeta, 
leads to the reduction of memory. When ZIP is administered immediately 
following an event or weeks to months afterward (when remembering the event) 
the subsequent memory of the event is eliminated (Shema, Kacktor, & Dudai, 
2007; Cohen et al., 2012). PTSD treatment research is moving in a positive 
direction. However, I still believe that the goal should not simply be to cure an 
individual’s symptoms but to help the individual grow out of his or her 
experiences and find meaning out of his or her suffering.  
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Although the research has begun to shift away from developing a 
preventative treatment for PTSD, it is still important to continue asking the 
difficult questions about potential treatments. It is important to realize that there 
is value in overcoming suffering. Although every individual should be able to 
function normally, suffering is a vital part of the human condition. Posttraumatic 
growth can be achieved in response to this suffering. In order for people to 
continue asking difficult questions, society needs a fundamental change of 
attitude. Frankl points out that “Life ultimately means taking the responsibility 
to find the right answer to its problems and fulfill the tasks which it constantly 
sets for each individual” (1985, p. 98). Each individual must realize his or her 
speck of the world and work to redeem his or her place. This may be support for 
an individual suffering from PTSD, a PTSD victim addressing his own struggles 
in a real and honest manner, or it may not have anything to do with PTSD. 
Regardless of circumstance, each individual has the ability to redeem a small 
portion of the world. Without question, the world can be a dark place, but 
sometimes it takes suffering to truly see the light that may be uncovered in the 
darkness. PTSD research must continue, but regardless of its outcome, 
individuals must continue working through suffering in a real and honest 
manner. 
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Upon completing this thesis project, I can honestly say that no other class, 
project, or assignment has contributed as much to my learning and personal 
growth as this project. Through the course and past fourteen months, I have 
learned much about PTSD and the possible treatments of the disorder, realized 
that the philosophical exploration of questions is just as important as scientific 
studies, and most of all, uncovered much about myself. Through the completion 
of this thesis, I have gained a better understanding of what I wish to do in the 
future and what my search for meaning entails. Just as I began this thesis project 
with a hope to integrate my beliefs into my thesis work, I look to conclude this 
thesis with a hope to continue questioning the topics that I have explored in this 
thesis, to continue to grow as a person, and to move forward in the search of 
meaning.  
My thesis project began with the scientific research I conducted on The 
effects of propranolol, a non-selective β-adrenergic antagonist, on rat behavior in an 
animal model of posttraumatic stress disorder. This study allowed me the 
opportunity to grow as a neuroscience student, to gain valuable research 
experience, and to learn about a psychological disorder that is important to me 
and an issue for those suffering from the disorder. Although I did not support 
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the hypotheses that I set at the onset of the study, I found significance in other 
areas of the study. According to the data collected, propranolol does not have a 
significant effect on PTSD-like symptoms in rats. The data also suggests that the 
animal model may not have sufficiently produced a model of PTSD. However, 
the present study did yield data concerning the time course of the presentation of 
PTSD-like symptoms, and also provided data suggesting that laboratory animals 
may perpetually be in a state of anxiety, potentially an animal-version of PTSD. 
This study challenged me to take the neuroscience knowledge I have learned in 
the classroom and apply it to real world issues. Through the process of designing 
and then carrying out a study, I have gained valuable research experience that I 
can take with me into my next stages of life. Through this study and greater 
thesis project, I have learned a lot about what it takes to further knowledge 
through scientific research.  
The study I conducted, as well as the greater thesis, revealed a lot of 
information about PTSD that I had not previously known. I have learned a great 
amount about the possible neurobiological mechanisms through which PTSD 
may be influenced. Additionally, I have learned that there is not and cannot be, 
at the current time, an adequate treatment for PTSD. Although there have been 
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many advances in research regarding the topic, no treatment has proved 
effective for the preventative or reactive treatment of the disorder minus 
significant side effects. On a more elementary level, this thesis has opened my 
eyes to the prevalence of PTSD and the issues that it creates for those suffering 
from the disorder and others involved in their lives.  
As I mentioned earlier, PTSD is an important topic for me. Although I do 
not have a relative suffering from PTSD, I do have three uncles and an aunt in 
the military, and my future career plans may include the military as well. I 
believe that I am blessed for not having to see them suffer from this disorder, but 
I know that they are at a greater risk for developing PTSD at some point during 
their lives. As I have gained a greater knowledge of the disorder, I have become 
aware of the issues that it may create and the struggles that are involved with 
overcoming one’s symptoms. I also know that I am passionate about easing 
suffering and continuing the work I have began in this thesis. In many ways, this 
thesis has influenced my outlook on the future. 
 Although this thesis has not changed my career plans of becoming a 
physical therapist, it has managed to change my outlook on the way I will live 
my life going forward. The researcher’s primary influence on my future is the 
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latent idea of allowing life to happen and learning from every experience. In the 
study, I did not find the results that I believed I would, but I did find other data 
that can inform PTSD research as well as the field of neuroscience. I believe that 
life often times throws curve balls, and although one may be completely 
prepared, things can go contrary to planned.  As I move forward, I will prepare 
for the future, but I will also learn from every instant, be flexible with the course 
that life takes, and be ready to take advantage of each stage of life.  
 The philosophical questions raised in The Afterword of this thesis, influence 
my life even more so than the research at the foundation of my thesis. Through 
the philosophical questions, I have learned that it is most important to ask tough 
questions and to formulate one’s own answers to those questions. From the 
scientific standpoint, it seems great to eliminate suffering and it is fascinating 
that a drug can numb the emotional context of an experience. However, this 
great scientific goal does not seem quite so marvelous when one asks the 
question: is the cost of eliminating memories or the emotional aspects of memory 
worth the benefit of reducing suffering? This question, forces an individual to 
think of the value of his or her memory, the value of his or her emotions, and the 
problems that may arise for society if a treatment is found. Nothing is as simple 
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as it seems. It is important to not accept things as right or wrong simply because 
one opinion is the general consensus. Instead, each person must ask his or her 
self tough questions and form his or her own answers to those questions. It is 
through the thought processes that one takes in answering such questions that 
truly informs the individual. Although the development of a treatment for PTSD 
is not a single person’s decision, the administration of a treatment does require 
one’s consent. Before consenting to a memory altering treatment, each person 
with the potential of developing PTSD must think of the consequences, both 
good and bad, that the treatment may have. As I move forward beyond Regis, I 
will continue to ask hard questions, to search for the answers to these questions, 
and ultimately to find meaning in my work and life. 
Along with the continuation of asking hard questions, I will also continue 
to take action towards the reduction of suffering. It is through action that a 
person can find his or her meaning in life.  Regardless of any trauma one has 
endured or any hardships that lie ahead, it is crucial for an individual to 
proactive and reactive.  Each person must take action by pursuing the 
achievement he or she wishes to see and striving for his or her own personal 
growth. Regardless of one’s beliefs on the value of suffering, it is true that today 
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is not yesterday, and every day that we live, we move closer to death. One must 
not live in the past or for the future; we must all live for today. Ultimately, by 
living in the moment and asking the hard questions that inform one’s life, one 
will find his or her meaning in the world, which is the art of Magis. 
Magis, Latin for more, is the Jesuit concept of living a life for the greater 
glory of God and continually striving to improve the world. The needs of the 
world become visible only through straining to see the way that the world truly 
is. One must strain to see the injustices that lie in front of them and the suffering 
that affects the lives of our friends, families, and fellow persons. About 7 billion 
people live on Earth, and each person has his or her own hardships and 
experiences with suffering. If you cannot imagine the quantity of 7 billion, 
simply multiply yourself as well as all your qualities, attributes, experiences, and 
imperfections by 7,000,000,000. The world is a massive place, and much of the 
time the individual gets lost in the expansiveness of the world. This is 
exemplified when Dillard cites Stalin as saying, “One death is a tragedy; a 
million deaths are a statistic” (2000).  All too often, suffering is generalized into a 
common phenomenon. If one is truly looking to live out the Magis, he or she will 
seek to find and make just the injustices in the world, and suffering will not 
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simply become a statistic. Although one is not able to redeem the entire world, 
no person is free to take no part in it. Each person must find his or her purpose 
by searching for the Magis every day and redeeming his or her own speck of the 
world.  
With the conclusion of this thesis, I near the end of my time at Regis 
University, and as I prepare to leave Regis, I am determined to remain passionate 
about the value of learning, the pursuit of knowledge, and the belief that asking 
hard questions leads to greater understanding. These are the things that Regis 
has instilled in me, and the reason that I chose to write a thesis that would test all 
facets of my intellect. I have also chosen this thesis topic because I found an 
injustice in world and hoped to redeem a small part of the injustice. Throughout 
this thesis, I have attempted to play a small role by creating awareness of PTSD 
and searching for a treatment. Through this thesis project, I have searched for the 
Magis, and I hope that this work has managed to redeem a speck of the world. 
Regardless of where life leads me after graduation, I will continue to search for 
the Magis, to redeem small specks of the world, and to run with full speed 
towards excellence. Furthermore, I promise to never lose sight of the man I have 
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